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                                             ABSTRACT 
 
 Siddha system of medicine is one among the traditional medical systems 
originated in India which has its foundations from superior wisdom of Siddhars. They 
are responsible for the Tamil medicine of the present day and also for many other 
sciences of public utility. 
 Raktha soorai vayu mentioned in siddha literatures may be co-related with 
poly cystic ovarian syndrome in modern medical science. Poly Cystic Ovarian 
Syndrome (PCOS) is one of the most common reproductive health problems suffering 
of women .It is considering as a problem of anovulation and infertility along with the 
symptoms of irregular menses , obesity, insulin resistance, hirsuitism, acne, 
androgenic alopecia and recurrent miscarriage. Treatment of PCOS may be enhanced 
in all aspects of syndrome including short term problems like acne & infertility as 
well as long term problems such as obesity. 
 Reviewing the modern science and Siddha literatures regarding PCOS, better 
understanding of symptoms, pathogenesis of PCOS and its proper line of Siddha 
treatment can be obtained. Various pre – clinical studies such as bio-chemical  , 
phytochemical , anti –microbial, hypoglycemic,hypolipidemic and toxicity studies 
were carried out for Karunjchirakam Chooranam and relevant results were obtained. 
 By this study, I planned to identify the PCOS syndrome early so as to 
encourage young women to seek timely treatment and prevent its long term 
complications.In most of the cases treated with Karunjchirakam Chooranam, better 
results were visible. All the concerned results were statistically analysed and found to 
be significant. 
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CHAPTER-I 
INTRODUCTION 
The Siddha medicine is one of the ancient systems of medicine founded by 
spiritual scientists called ‘Siddhars’. They had more evolved consciousness that 
allowed them to investigate, understand and share the relationship between human 
and nature. They had already illustrated that the universe and humans were made up 
of five elements- earth, water, fire, air and space and also told that the three humors 
(vatham, pitham and kapham) are made up of five elements. Most of the siddha 
medicines are formulating from herbal and mineral sources. Siddha medicine is based 
on Pancha Bootha theory. 
 
The ratio between vatham, pitham and kapham are 4:2:1 respectively. At the 
onset of disease, one of the humor levels is changed, causing an imbalance. The line 
of treatment is dictated by which humor is abundant and by how much. The goal of 
treatment is to restore the perfect balance of the three humors. The exponents of this 
system emphasize on achievement of this state via medicines and meditation. It was 
quoted by Thiruvalluvar as follows, 
 
“lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~Ozii<!
utq!Lkzi!w{<{qb!&e<X”!
.!kqVut<Tui<!
The treatment aspect involves the neutralization of affected humors. 
! uqOvsek<kiz<!uikl<!kiPl<!!
ulek<kiz<hqk<kl<!kiPl<!
fsqb!nR<sek<kiz<!ghl<kiPl<!
! ! ! .Ofib<!fimz<!Ofib<!Lkz<!fimz<!higl<!.!2!
!
Vatha kutram is neutralized by viresanam (purgative). Pitham is neutralized by 
vamanam (emetics). Kapha kutram is neutralized by anjanam and nasiyam 
(application of medicine in eyes andnose). 
According to the siddha medicine, various physiological functions of the body 
are attributed to the combination of seven basic tissues: They are as follows 
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1. ooneer (plasma) responsible for growth, development and nourishment; 
2. seneer (blood) responsible for nourishing muscles, imparting colour and 
improving intellect; 
3. oon (muscle) responsible for shape of the body; 
4.  kozhuppu (fatty tissue) responsible for oil balance and lubricating joints; 
5. elumbu (bone) responsible for body structure and posture and movement;  
6. elumbumajjai (bone marrow) responsible for formation of blood corpuscles ; 
7. sukkilam (semen) / sronitham(ovum) responsible forreproduction. 
 
The siddhars had classified diseases into 4448 in number. There is another 
concept based on kuttram basis (humoural basis) viz 80 vatha diseases, 40 pitha 
diseases and 20 kapha diseases. In this modernized mechanical world, peoples are 
suffering from various pattern of diseases. Considerably females are the majority of 
sufferers due to their role in family as well as society. Since the diseases due to 
endocrine disorder are unnoticeable due to their ignorance.Usually these disorders 
leads to moderate as well ascomplications. 
 
Polycystic ovarian syndrome (PCOS) is thought to be the most common 
endocrine disorder found in women. PCOS impacts women of all races and 
ethnicities who are of reproductive age. In unspecified populations the prevalence of 
PCOS has a reported incidence rate of 3-10%. PCOS is a syndrome that is 
characterized by an imbalance of the sex hormones. Common symptoms include 
irregular menstrual cycle, polycystic ovaries, and hirsutism. Features of the syndrome 
may also include fertility, insulin-resistance, impaired glucose tolerance and 
dyslipidemia due to increased risk factors. The etiology of PCOS is not completely 
understood and there is no known cause, although a genetic component and 
diet/lifestyle factors, such as insulin resistance and obesity have been identified .  
Giving a patient the diagnosis of PCOS makes the patience aware of possible fertility 
concerns, dysfunctional bleeding, endometrial cancer, obesity, diabetes, dyslipidemia, 
hypertension, and the theoretical increased risk of cardiovascular  disease. Since 
PCOS could be genetic, it may bring awareness to family members and future 
children. It is an important for the field to reach the level of comprehension with 
PCOS to the extent that diabetes and metabolic syndrome established to improve the 
quality of life  for these women. 
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In siddha literature Yugimuni vaithiya kaviyamhas explained about 
RakthaSoorai Vaayu with the symptoms of amenorrhoea, dysfunctional uterine 
bleeding, oligomenorrhoea, pelvic pain, heaviness of thigh, threatened abortion. All 
the symptoms and signs can be correlated with Poly Cystic Ovarian Syndrome in 
modern medicine. 
 
So,I have to chosen the herbal drug KARUNJCHIRAKAM CHOORANAM  
in a classical siddha  single preparation KARUNJCHIRAKAM CHOORANAM 
mentioned in Gunapaadam Mooligai Vaguppu- muthal paagam pg no.463 for the 
treatment of RAKTHA SOORAI VAAYU (Poly Cystic Ovarian Syndrome). 
 
Rationale: 
KARUNJCHIRAKAM CHOORANAM is the herbal siddha formulation taken 
from the classical siddha literature. The  trial medicine is choosen to evaluate the 
efficacy of treating  polycystic ovarian syndrome .It was  estimated to be useful for 
this disease because it possess medicinal activities like anti-
hyperlipidemic,emmenagogue, anti –hyperglycemic, analgesic, anthelmitic, anti-
microbial, anti-iflammatory, spasmolytic, anti oxidant properties. 
 
According to literature references and existing research work done in this 
medicine,it was revealed that due to its emmenagogue and anti-spasmodic properties 
it is convenient and safe for the management of polycystic ovarian syndrome. 
 
Extraction of the seeds showed better recovery of phenolic compounds than 
HD SFE and proved the occurrence of thermally labile or photosensitive bioactive 
volatiles of four major quinonic phenol compounds  
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CHAPTER-II 
AIM AND OBJECTIVE 
AIM 
To clinical  document of the efficacy in KARUNJCHIRAKAM 
CHOORANAM (Internal Medicine) in the management of Raktha Soorai Vaayu 
(Poly Cystic Ovarian Syndrome) 
 
OBJECTIVES 
Primary Objective: 
To evaluate the therapeutic efficacy of KARUNJCHIRAKAM CHOORANAM 
(Internal medicines) in the treatment of Raktha Soorai Vaayu(Poly Cystic Ovarian 
Syndrome) 
 
Secondary Objective: 
● To evaluate  the bio-chemical and pharmacological parameters of trial drug 
• To evaluate the safety profile of the trial drug in animal models(OECD 
guidelines). 
•  To analyse the siddha diagnostic methods (Envagai thervugal) in Raktha 
soorai vaayu. 
• To have an idea of incidence of the disease with reference to age, occupation, 
marital status, habitetc. 
• To evaluate the infertility ratio among the studypatients. 
• To study the changes in USG Pelvis before and aftertreatment. 
• To compare the BMI (Body Mass Index) before and aftertreatment. 
• To analyse biostatistics approach documentation of clinical evaluation in 
Raktha SooraiVaayu 
• To collect both siddha and modern literatureevidences. 
 
Justification of research : 
 Polycystic ovarian syndrome is a common issue which leads to complications 
like infertility ,if it ts not properly treated. prevalence of PCOS ranging from 2.2% to 
26%.most reports have studied adult women with age ranged from18 to 45 years 
.Nowdays for the treatment and diagnosis many sophisticated methods are available 
but it is very expensive and time consuming.              
 
 This study aims to asses symptomatic presentations, prognosis of treatment 
with herbal formulation which is mentioned in valuable literature.  
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CHAPTER-III 
REVIEW OF LITERATURE 
3.1 IN JOURNAL 
 
 
 
 
 
 
 
 
 
The various journals to collections related to Karunjchirakam (Nigella sativa). 
 
TAXONOMY  
Kingdom    – Plantae-plants  
Superdivision  spermatophyta  – Seed plants 
Division magnoliophyta   – Flowering plants  
Class magnoliopsida   – Dicotyledons       
Subclass     – Magnoliidae          
Order      – Ranunculales     
Family     – Ranunculaceae                                                                                  
Genus      – Nigella   
Species    – Nigella sativa 
MACROSCOPIC. 
SHAPE  : Pear –shaped with slightly curved taperedends. one   
sideis flat and the other is convex. The surface is 
slightly and regularly embossed. 
COLOR : Black with hints of light grey. 
SIZE  : Length 4.1cm ,Width 2.0 cm . Transversal cross-section  
often hexagonal. Longitudinal cross – section is pear 
shaped. 
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FLAVOUR AND TASTE EVOLUTION:  
Metallic taste when the seed comes into contact with dental enamel. After 
crushing,   taste of lead pencil, followed by sharp,aromatic.  
Peppery taste,becoming irritant at the base of the throat and leaving a 
strongbitternesspersist on the palate. 
 
CRUSHING: 
Easy with dissociation of tissues 
 
Microscopic characteristics: 
• Brick red external legment consisting of polygonal cells (penta-to heptagonal) 
with coloured albumen &consisting of thin walled cells with several oil 
droplets. 
• Tissues surrounding are very slightly embossed. 
• Grey –the albumen is orangey –brown consisting of a single layer of  
polygonal cell (square) with are often aligned  
 
Chemical composition of nigella sativa L.seed extracts obtained by supercritical            
carbon dioxide :  
Sureh kumar  et al(2010)  has studied chemical composition of black cumin 
(nigella sativa  L) seed extracts obtained by supercritical carbon dioxide at two 
different conditions that result  in total extract (28mpa/50 c,SFE1) and major volatile 
part (12 MPA/40 C ,SFE2)and essential oil optional by hydro distillation of sfe-1(HD 
SFE ) .SFE have been carried out to characterize  the compounds and variation of 
quoins of phenolics .The extract were analysed by GC  and GC-MS  and the presence 
of phenolic  compound was further confirmed bby 2D  HSQCT 1H and 13 C NMR  
spectroscopy. 
 
Forty  seven volatile compound were reported detected where sixteen 
compound were reported  for the first time in the oil of this  seed, moreover, 
thymoquinone( TQ)  and thymol (THY) were the major phenolic compounds.  
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DIABETIC  NEPHROPATHY : 
Phytochemical analysis Haddad.A .et al (2017)was studied the  
spectrophotometric  evalvation of the antioxidants (fdlavonoids and carotenoid) 
Showed that nigella sativa  seed contains 993.6 mg |100 g dry weight  flavonoids  and 
80.6 mg \100g  dry weight  carotenoids .whereas propolis contains 4630 mg \100 g 
dry  weight flavonoids and 1.92 mg \100 g  dry weight carotenoids 
 
FASTING BLOOD SUGAR (FBS)           
Haddad.A .et al(2017) was studied the  effect of treating STZ induced diabetic 
rats 1.the mean values of serum fasting blood sugar (FBS) Were significantly 
(p<0.001) increased in the positive control group .when compared with those of the 
negative control .however ,treating  these rats with methanolic extract of nigella 
sativa and propolis for 4  weeks significantly (p\0.001) reduced the fasting blood 
sugar in the serum og both G3 and G4 groups .Respectively although being higher  
than  of the negative control values methnolic extract of propolis in G4 was more 
effective in reducing fasting blood sugar than of nigella sativa in G3 
 
ANTIOXIDANT AND ANTIMICROBIAL ACTIVITIES 
Sunita singh et al(2014) was studied seeds of black cumin seed to possess 
magical showed and have been worked out extensively  revealed that black cumin 
essential oil and its oleoresins constitute a good alteranate source of essential fatty 
acids compared with common vegetable oil. The present results showed that essential 
oil and oleoresins of black cumin exhibited higher antioxidant activity than synthetic 
antioxidants  
 
ANTIBACTERIAL  POTENTIALS OF NIGELLA SATIVA: 
Hera Chaudhry et al(2015) was studies plants products are rich sources 
phytochemicals as is the extract of this study and have been found to possess a variety  
of  biological activites including antioxidant cytotoxic and hapatoprotentials 
potentials they are excellent reducing agents and reverse oxidation by donating 
electrons and \or hydrogen ions [49]study was carried out of exploit the potential of 
n.sativa epicotyl suspension culture of N.sativa under the effective of biotic and 
abiotic elicitation .results showed that MnCl2 elicitation enhanced the production of 
thymoquinone and thymol             
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ANTI  INFLAMMATORY AGENT IN ACTION : 
Mukhtar Ikhsan et al(2018) was studies Nigella  sativa has a broad spectrum 
of pharmacologicals actions, including antioxidant, antidiabetic anticancer, 
antitussive, immunomodulator analgesic. antimicrobial, anti-inflammatory, 
spasmolytic, and bronchodilator. 
 
LIPID LEVELS AND HYPOGLYCEMIC ACTION: 
Ahmed Badar et al was(2017) studies thenigella sativa group had a significant 
decline in TC,LDL.TC\HDL AND LAL-C rations .compared with the respective 
baseline data  and the control group HDL-C was significations elevation in the nigella 
sativa.Datau EA and Kaatabi et al was studies  Type 2diabetic with 
hypercholesterolemia they recevived 2g n.sativa per day for weeks .this resulted in a 
signification decrease in TG,TC.LDL-C ;however it indicated that n.sativa  has no 
beneficial effects on fasting blood sugar and HDL-C more over a nonsignificant 
reduction in lipids has reported in in adults who received powdered n –sativa seeds 
and men withy central obesity treated with nigella sativa. 
 
3.2GUNAPADAM  ASPECT -KARUNJCHIRAKAM 
Botanical name  :  Nigella sativa 
Synonyms  :  Aranam, Upakunjikai 
NAMES 
Tamil : Karunjeeragam 
Hindi : Kulanji ,Kala-Zira 
Telugu  : Nalla-jilakarra ,Ulli Ginjalu 
Karunjeeragam part used : Seeds 
Properties : 
Suvai (Taste) : Kaippu 
Thanmai (Nature) : Veppam 
Pirivu (Bio-Transformation) : Kaarppu 
ACTIONS: 
Carminative 
Diuretic 
Emmenagogue 
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Galactogogue 
Anthelmintic 
Stomachic 
Parasiticide 
Emollient 
 
Ingredients and medicinal  uses of  Karunjeeraga chooranam : 
TAMIL  NAME Pharmacologigal Actions 
THERAPEUTIC USES IN  
SIDDHA 
Karunjeeragam Antihypertensive  
Emmenagogue  
Diuretic  
Liver tonic  
Analgesic  
Anti bacterial  
Anti diabetic  
Anti cancer  
Immunomodulator  
Bronchodilator  
Anti oxidant 
Soothaga kattu  
Soothaga soolai  
Karappan  
Thalai noi  
Kan noi  
Vanthi  
Kaamalai  
Irumal 
 
3.3 SIDDHA ASPECT – RAKTHA SOORAI VAAYU 
Siddha system of medicine has its own treasure regarding gynecological 
diseases and its management. Siddha literatures clearly states about the concepts of 
puberty, menarche, menstruation, conception, contraception and pregnancy, labor, 
sterility and mentioned about disorders of menstruation. Primarily,inflammation 
infection and neoplasmic changes causes diseases of female urinary tract . 
 
Maan murikiyam quotes menstrual diseases as follows, 
!
!
!
!
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H,h<H!Ofib<gt<!< < << < << < < !
“H,h<Hg<!gijz!OfiU!lqGkz<!!
Ljxh<hc!fitqe<!Le<H!H,k<kz<!!
nf<ki!ofz<jz!bge<X!H,k<kz<!!
kqr<g!tqVLjx!Ll<Ljx!H,k<kz<!!
GVkq!bVgz<!lqGf<k!Okie<xz<!!
gXk<kz<!outqxz<!gPfQv<!fqxr<ogitz<!!
kq{qf<K!GVkq!K{qf<K!uQp<kz<!!
lqgg<ogM!fix<xl<!uQsz<!Fjvk<kz<!!
Jf<K!fitqe<!lqg<ogip!gqMkz<!!
sjkk<kqvt<!Okie<xz<!wElqju!hqxUl<!!
gVh<jh!utqbqEl<!hqxuqEf<!Okie<Xl<!!
H,h<H!Ofib<g!tiole!olipqh”!!
.lie<LVgqbl<!
POOPU (Menstruation) 
Definition 
It is a normal phenomenon of a female characterized by bleeding through the 
vagina once in 27 days after attaining puberty. Normally the bleeding occurs for 3 to 
5 days. 
“H,h<oheh<!hMuK!H,jubv<!klg<Gg<!!
gVUXh<!hqx<hM!gpqUs<!osl<Hez<!!
lkqOkiXl<!nz<Gz<!upqoutqh<!hmOz”!!
From ovaries the ovum is released once in every month alternatively before the ovum 
reaching the uterus. If got fertilized it is implanted in endometrium of the uterus. 
“gVg<gi!bqv{<cE!LVg<ogitk<!Okie<xqg<!!
gVh<jh!Bm<HGr<!GVkqg<!gzh<hiz<!!
gVk<Okiz<!Okie<Xf<!kqr<gt<!OkiXl<!!
nKOu!gVh<jhbq!Em<Suv<!siVl<!!
nk<Okiz<!-bz<hqe<!njlf<kqMl<!jhBt<!!
gVuqjt!Lx<Xl<!gig<Gl<!ohiVm<jm”!
If the ovum is not fertilized, it shrinks and the endometrium is disintegrated. Then it 
is expelled out through the vagina as normal menstrual bleeding. 
“gVs<ose<X!xjlf<kqz!kibqe<!nk<Okiz<!!
sqjkf<K!gpZf<!kqr<gt<!OkiXl<!!
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nk<Okiz<!sqjkkzqe<!Ngqb!osf<fQv<!!
Gxqupq!outqh<hmz<!H,h<ohe!olipqh<!!
-bl<hqb!fiOti!vqVhk<!OkOp!!
Okijgbv<!H,h<Hk<!Okix<xg<!gizl<”!
Raktha Soorai Vaayu – a disease comes under karpa rogam described in Yugimuni 
vaithiya kaviyam. 
DEFINITION OF RAKTHA SOORAI VAAYU 
Also known as soothaga vaayu.It is generally presented with symptom of 
congestion of the womb due to the accumulation of blood due to the deranged vaayu. 
 
The symptoms includes very acute pain of a darting character shooting down 
the thighs, pain in the lower part of the bowels, pain in the groins, nausea and 
sometimes vomiting just before or during the menstrual period. 
This may even tend to prevent conception. 
 
AETIOLOGY 
The text Agathiyar Kanmakaandam says the reasons for Karpa Noigal are due 
toanykindofinfanticide,takingthecow’smilkwithoutforcalf, destroyingthe 
Youngcrops. 
“Spzilz<!oh{<gTg<Gg<!ogx<hOfib<!kie<!!
$p<f<K!uf<K!gVlk<jks<!osiz<zg<OgT!!
npziOz!uqf<Kujg!bpqk<k!hiu!!
lR<silx<!hizgjeg<!ogie<xhiul<!!
Gpuqbqtl<!hqR<S!H,h<hxqk<k!hiur<!!
Ogiuqer<gt<!hVGl<hiz<!Gck<khiul<!!
uqjtuie!uqtl<hbqjv!bpqk<khiu!!
Olkqbqeqz<!lzmie!uqf<jk!kiOe”!!
.ngk<kqbv<!ge<l!gi{<ml<!!
h/w{<;47?!himz<!w{<;215!!
 
The text Thanvanthiri vaithiyammentioned about the causes of  karpa noi as 
the following. Due to toxic substance (Philter), increased sexual desire, accumulated 
postpartum blood in the womb, derangement of vatha kutram. 
“uR<sje!ke<eqeiZl<!lVf<kQM!ke<eqziZl<!!
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oliR<sqM!svQv!Oum<jg!BXkqosb<!k{<ch<hiZl<!!
nR<szil<!hqt<jt!Ohxq!zmr<gqb!-vk<kk<kiZl<!!
lqR<sqb!uiBuiZl<!gVh<hOfib<!OlUole<Oe”!!
.ke<uf<kqvq!juk<kqb!higl<.2!!
h/w{<;362!himz<!w{<;72!!
 
CLASSIFICATION  
ogv<h<hOvigl<!ujggt<;!< < < << < < << < < < !
In Yugimuni vaithiya kaviyam six types of diseases are described under the 
Karpa noigal. 
 ogv<h<hOvigl<!!
 ogv<h<huqh<HVkq!!
 ogv<h<huiB!!
 SOvi{qkuiB!!
 -vk<k$jvuiB!!
 ogv<h<h$jz!!
 
Athma Rakchamirtham Ennum vaithiya sara sangiraham 
Under the topic karpakol the following diseases are described. 
 
 -vk<ks<$jz!
 ogv<h<huqh<HVkq!
 $kguiB!
In sarabendra vaithiya muraigal!
In sarabendra vaithiya muraigal – Garpini bala rogasikichai 
The following diseases are described under KarpaRogam 
 ohVl<hiM!!
 lzm<MOvigl<!!
 ogv<h<huqh<HVkq!!
 ogv<h<huqmOvigl<!!
 ogv<h<hs<!$jz!!
 -vk<k!$jz!!
 
In Mega noi, soothaga nool mattrum arivaiyar chinthamani 
Karpa noigal is classified into six types 
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 ogv<h<huiB!
 SOvi{qkuiB!
 dkqvuiB!
 -vk<kGe<luiB!
 $kguiB!
 gVg<GpquiB!
CLINICAL FEATURES 
A. In yugi muni vaithiya kaviyam 
-vk<ks<!$jv!uiBuqe<!G{l<;< < < << < < << < < < !
! “kqv{<M!hqv{<M!gQp<ubqx<xqz<!kqvlib<likuqmib<!OkiXl<!nv{<Ml<!
! GVkqlqVf<K!uqPl<!njvBl<!KjmBl<!djtg<Gl<!lqg!kqv{<M!
! sqzfit<!sqg<gq!fqx<Gl<!kqVuiv<!gVjunpqk<K!uqMl<!dV{<m!
! -vk<k!$jv!we<x!uib<oue<Xjvk<kiv<!d{v<f<OkiOv”!
! ! ! ! ! ! .!B,gqLeq!juk<kqb!giuqbl<!!
hg<g!w{<;211?!himz<!w{<;43!
The manifestations of Raktha soorai vaayu are 
 Excessive bleeding(menorrhagia) 
 Pain present in the thighs andgroin 
 Absence of menstruation (Amenorrhoea) 
 Miscarriage 
B) Athma Rakchamirtham Ennum Vaithiya Sarasangiraham 
2/-vk<k$jzg<!G{l<< < << < << < <!
The manifestations of Raktha soolai are, 
 Painfulmenstruation (Dysmanorrhoea) 
 Abnormal heavy or prolongedmenstruation 
 Miscarriage 
“hiv<k<kqmOu!lr<jgbv<g<G!vk<ks<$jz!!
hgXgqOx!ecubqx<jxh<!hx<xq!fqx<Gl<!!
Ogiv<k<kqmOu!BkqvlK!kqv{<MOl!kie<!!
ogikqh<ohMk<K!likuqmib<!gizf<ke<eqx<!!
Osv<k<kqmOu!$kgr<gt<!lqGf<K!gi[R<!!
sqXupqbib<g<!gVupqBl<!hqv{<Mjtg<Gl<!!
Wv<k<kqmOu!KjmbqMh<H!Ujts<sziGl<!!
-vk<kliR<!$jzG{!lqKkie<!hiOv”!!
.Nklvm<silqi<kole<El<!juk<kqb!sivsr<gqvgl<!h/w{<;59!!
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3/!$kguiB!
The manifestations of soothaga vaayu are 
 Derangement of vaayu results in painfulmenstruation 
 Headache 
 Central obesity 
“OgTOl!$kgk<kq!zg<gqeq!uib<U!!
ogMk<KuqM!likuqmib<!gm<ch<!OhiGl<!!
NTOl!gVg<GpqBf<!K~f<K!Okgl<!!
nh<hOe!BkqvlK!nc&zk<kqz!
fQTOl!$kgk<kqz<!uib<U!Okie<xq<!
Ofvie!ncubqX!uzqh<Hg<gi[l<!!
hiTOl!kjzuzqg<Gl<!ubqXjtg<Gl<!!
hg<Gulib<!lVf<K{<{k<!kQVf<kiOe”!!
! ! ! ! .Nk<lvm<silqv<kole<El<!juk<kqb!sivsr<gqvgl<!!
h/w{<;61!
C. In Dhanvandhri vaithiyam – Muthalbaagam 
Under the topic soorai nithanam 
1. The manifestations of Raktha sooraiare 
 Infrequent menstruation 
 Giddiness 
 Amenorrhoea 
 Miscarriage 
 
-vk<k$jv!<<< !
“kqv{<M!Hv{<M!gQp<ubqx<xqz<!kqxlib<!likuqmib<!OhiK!!
lV{<M!GVkq!GXgquVl<!uib<fQv<!ohVk<K!lbr<gquVl<!!
kqv{<M!sqzfim<!sqg<gq!fqx<Gl<!kqxlir<!gVju!bpqh<hqg<G!!
LV{<m!uqvk<k!$jvobe<X!LXg<G!{r<g{<MjvhQOv”!!
.ke<uf<kqvq!juk<kqbl<!Lkz<!higl<!!
h/w{<;347?!hi/w{<;37!!
!
2. The manifestations of Karba suronithamare 
 Painful and infrequentmenstruation 
 Nausea 
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 Giddiness 
 Amenorrhoea 
 Miscarriage 
 
 
gv<h<h!SOvi{qkl<< < << < << < <!
“kqv{<M!Hv{<M!gQp<ubqx<xqz<!kqr<gt<!LPg<gqz<!uzqB{<mi!!
lV{<M!GVkq!uVl<!uib<fQVX!lbr<gquVf<!kqv{<M!!
sqzfim<!sqg<gq!fqx<Gl<!kqxlir<!gVju!bpqh<hqg<G!
LV{<m!gv<h<hs<!SOvi{qk!ole<Xjvg<Gr<!G{r<!g{<mxquQOv”!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.ke<uf<kqvq!juk<kqbl<!higl<.!J!
h/w{<;364!hi/w{<;77!
!
D. In Sarabendra vaithiya muraigal – Garpini Bala Rogasikichai 
Under the topic Sthrikalin Rogangal 
The manifestations of Raktha soolai are 
 Lower abdominal distension withvomiting 
 Painfulmenstruation 
 Excessive menstrual flow(menorrhagia) 
 Pain in the thighs (a part ofdysmenorrhea) 
 Delayed / irregular menstrualcycle 
 Miscarriage 
 
-vk<k$jzg<!GxqG{l<< < << < << < <!
“kqv{<M!Hv{<M!gQp<!ubqx<xqz<!kqxlib<!likuqmib<!ohx<X! !
! dV{<M!GVkq!lqGkquqP!Ljxf<KjmB!Ljtf<K!uVl<!
! kqv{<M!sqz!fit<!sqg<gq!fqx<Gl<!kqxlib<!gVjubpqh<!hqg<Gl<!
! dV{<mbqvk<k!$jzobe<X!dXkqbqju!ogi{<MjvbQOv”!
.svOhf<kqv!juk<kqb!Ljxgt<!
!! ! ! ! ! .gv<h<hq{q!hizOvig!sqgqs<js!h/w{<;!53!
!
E. In silerpana noi mattrum uthara noi thohuthi – Edited byT.Mohanraj 
Under the classification of uthara noi 
The manifestations of Raktha soolai vaayu are 
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 Acute pain shooting down thethighs 
 Lower abdominal distention withvomiting 
 Pain in the lower part of thebowels 
 Menstrual bleeding inclots 
 Miscarriage 
-vk<k!$jzuib<U< << << < !
“kqv{<M!Hv{<M!ncubqx<xqz<!
kqxlib<!-vk<kl<!gm<cbkib<!
dV{<M!GVkq!kqv{<M!uVl<!okijmBl<!!
ubqXl<!djtf<K!uVl<!
kqv{<M!sqz!fit<!sqg<gq!fqx<Gl<!
kqxlib<g<!gVju!npqh<hqg<Gl<!
dV{<M!-vk<k!$jzuib<U!dXkq!
g{<M!djvk<OkiOl”!
! !
“hiv<k<KmOu!lr<jgbv<g<G!ovk<k!$jz!
hgVgqOxe<!ncubqX!gek<k!gi[l<!
Osv<f<kqmOu!dkqvlK!kqv{<MOl!kie<!
ogikqh<H{<mil<!likuqjm!gizf<ke<eqz<!
Osv<f<kqmOu!$kgUl<!lqGf<K!gi[l<!
sqXupqbib<g<!gVupqg<Gl<!hqv{<MjtBl<!
Wv<k<kqmOu!okijm!-Mh<H!djts<sz<!NGl<!
-vk<k!$jz!uiBoue!six<xziOl”!
.Osx<he!Ofib<!lx<Xl<!dkv!Ofib<!okiGkq!!
h/w{<;3:2?hi/w{<;227?228!
!
F. In Mega noi, Soothaga nool mattrum arivaiyarchinthamani 
The manifestations of soothaga vaaivu are 
 Infrequent menstruation 
 Lower abdominalpain 
 Headache 
 Generalized bodypain 
 Loss of appetite 
 
!
!
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$kguib<U!<<< !
“hikoliM!$kg!uiBuK!ke<jl!Ogt<!!
! likuqjmbK!GjxBOl!!
HgPvqb!ubqX!geligq!bkq!Oukje!!
! ncubqX!H{<Ohiz!Ofiuil<!!
OhikLX!ose<equzq!ds<sqbkqOz!Gk<K!
! -V!ogir<jgbK!LjtBOl!
Olikqbkq!kibqV!jggiz<!gqMg<GOl!
! giz<!l{<j{bK!LjtBOl!
Lkqb!fiuieK!uPuPh<hibqMl<!
! ne<el<!Gjxf<K!uVOl!
fQkLX!OleqbK!uqtElkq!Osihlib<!
! osix<hel<!nkqgvqg<Gl<!
fqk<keVt<!ohx<x!Leq!osiz<Z!
! Ljxbqe<!hc!osf<klqpi!Bjvk<Oke<”!
.OlgOfib<?!$kgF~z<!lx<Xl<!nvqjubv<!sqf<kil{q!!!!!!!!!!!!!!
hkqh<hisqvqbv<!U/Olige<vi\<!
!
G. Thiruvalluva Nayanaar –“Gnanavettiyaan-1500” 
In Gnanavettiyaan-1500, Thiruvalluva Nayanaar wrotes as follows 
 Vatham decreases in its place and get increases in pitham and kabamregion 
 Vatham gets decreases in ovary resulting in accumulation ofwater 
 Kabam gets increases and may results in increased bodyweight 
 
“$kgk<kqz<!uib<uKOhib<s<!osig<Gr<!gijzs<!
SVkqobEl<!ue<eqhqk<kf<!Kj{bib<s<!OsVl<!
likuqmib<!figlKl<!u^<Kg<!gm<Ml<!
likif<kl<!gm<cekiz<!liKOkgl!
DK!dmz<!svQvolz<zir<!gVh<jh!Kf<K!
dkqvfQv<!$sqgi!uib<Uf<k<!Okie<xq!
uikjebiz<!ubqXml<H!ohVk<K!Dkq!
lgk<kie!nc&zl<!uikR<!Osv<f<Ok”!
.Rieoum<cbie<.!2611!
 
H. Thirumoolar school of thought: 
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“$kie!lilqsl<!Spqk<kqcz<!gv<h<hk<kqz<!
uikie!Olgk<kiz<!upr<gqs<!oseqh<hqg<Gl<”!
.kqV&zv<!gVg<gqjm!juk<kqbl<!
 
 
I. Pararasasekeram: 
The manifestations of karbavaayu are 
 Amenorrhoea 
 Dysmenorrhoea 
 Constipation 
 Obesity 
 
ogv<h<h!uiBuqe<!G{l<;< < < << < < << < < < !
“ohiVL!Lkvf<!kjebjmk<Kh<!Ohik!lqgUl<!uzqB{<mib<g<!
GVkqgpqbqz<!uzqkQVr<!ogit<Tr<!ogv<h<h!Lxuzqg<Gl<!
uVc!bqMh<Hk<!KjmBjtB!lbg<G!lzk<jk!lqguqXg<Gl<!
ohVgh<!hj{g<Gl<!Lkvk<kqx<!OhSl<!ogv<h<h!uiBuqOk”!
 
Lg<Gx<x!OuXhiM< << << < !(Pathology) 
In siddha system the manifestations of all diseases are due to the derangement 
of tridoshas i.e., vatham, pitham, kapham 
 
Vatha kutram: 
Vatham in its normal condition, it maintains a state of equilibrium between 
different humors and the root principles of the body. It also tends to maintain uniform 
state in the metabolism of the body and helps the organs to discharge their specific 
function. 
uiB.!fvl<hqe<!upqbib<!uikfQv<!nkqgvqk<K!nhiek<kqz<!fvl<hqe<!upqbiBl<!
OuX!hx<hz!upqbiBl<!-xr<gq!d{<miGl<!Yv<!uik!Ofib</!
-T.V.Sambasivam Pillai Agarathy Vol – V 
 
The following vaayu are affected in Raktha Soorai Vaayu 
Abanan - Irregularly menstruation, Miscarriage Viyanan -  
Tenderness in the lower abdomen, fatigue. 
!
!
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hq{qbxqLjxjl!(Diagnosis) 
In piniyari muraimaigal following principles are followed in Siddha system 
They are 
Poriyaalarithal - Inspection  
Pulanaalarithal - Palpation  
Vinaathal  - Interrogation 
Poriyaal arithal: 
Porigal is the five sense organs of perception namely nose, tongue, eye, skin, 
and ear. 
 
Pulanaal arithal: 
Pulangal is the fire senses namely smell, sound, taste, sight and sensation. 
Physicians use their pori and pulan to examine the pori and pulan of the patient 
respectively. 
 
Vinaathal: 
Getting informations about the history of the diseases from the patient or from 
the attenders of him, when the patient is not in a position to speak or if the patient is a 
child. 
 
ENVAGAITHERVUGAL: 
 “kv{qBt<t!uqbikq!ke<je!bm<mir<gk<kiz<!
! ! kiexqb!Ou{<MuK!ObOki!oue<eqz<!
! kqv{qbOkiv<!fic!g{<gt<!sk<kk<OkiM!
! ! Okgk<kqeK!hvqsl<!uV{l<!fig<G!
! bqv{lz!&k<kqvlilqju!gotm<Ml<!
! ! bqkl<hm!Oukie<!hiv<k<Kg<!Gxqh<Hr<!g{<M!
! hveVtiz<!ohvqObiv<gt<!hikl<!Ohix<xqh<!
! ! h{<H!kuxilz<!h{<ckR<!osb<uQOv”!
! ! ! ! ! ! ! .G{uigm!fic!
 
The prime method adopted to diagnose the disease is by means of 
“Envagaithervugal”. The value of envagaithervugal is very important for diagnosing 
purposes, which is the unique and special method describing in Siddha system of 
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medicine. Envagai thervugal are 
“fich<!hvqsl<!fifqxl<!olipqupq!
lzl<!&k<kqvlqju!lVk<KuviBkl<”!
.!Ofib<!fimz<!Ofib<!Lkz<!fimz<!kqvm<M!
.!Lkz<!higl<!h/w{<.!381!
 
“fQcb!uqpqbqeiZl<!fqe<x!fig<Gxqh<hqeiZl<!
uicb!OleqbqeiZl<!lzoliM!fQvqeiZl<!
$cb!uqbikq!ke<jes<!Sgl<!ohx!nxqf<K!osiz<Oz”!
.ngk<kqbv<!
“olb<g<Gxq!fqxk<okieq!uqpq!fiuqVlzl<!jgg<Gxq”!
.sqk<k!lVk<Kul<!Ofib<fimz!
a. Naadi (Pulse) 
b. Sparisam(Palpation) 
c. Naa(Tongue) 
d. Niram (Colour of theskin) 
e. Mozhi (Speech) 
f. Vizhi(Eyes) 
g. Malam (Stools) 
h. Moothiram(Urine) 
 
Naadi 
The naadi indicated the state of udal thathus whether normal or abnormal.  
“Ofib<fic!Ofib<Lkz<!fic!nKk{qg<Gl<!
uib<fic!uib<h<hs<!osbz<”!
.kqVut<Tuv<
In Ratha Soorai Vaayu the vathanaadi or vathathonthanaadigal were seen 
commonly. 
“hivqb!uib<U!hvqf<K!GPh<Hgqz<!
kivqg<!gpqf<K!skfqk<kr<!%h<hqMl<!
uivq!dml<ohzil<!uzqg<Gl<!-jmOfiGl<!
Nvqbe<!osie<eie<!nxqf<kuv<!sqk<kOv”!
.hkqo{e<!sqk<kv<gt<!fic!si^<kqvl<!!
h/w{<;:6?!hi/w{<;:1!
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Vaayu stays in uterus and causes miscarriage and generalized body pain. 
“sqk<kie!gv<h<hk<kqz<!Osv<f<kqMl<!-vk<kf<kie<!
uk<kil<!UV{<M!uiB!Ohiz<!YcMl<!
dx<x!hsqOhiGl<!dpe<Ox!-jvf<kqMl<!
ux<xig<!gpqs<szil<!ue<!$kg!uiBOu”!
.hkqo{e<!sqk<kv<gt<!fic!si <^kqvl<!!
h/w{<;:5?!hi/w{<;!:2!
ACCORDING TO SATHAGANADI, Vaayu and blood stagnant in uterus 
causes soothagavaayu. 
 
Sparisam 
Tenderness felt over the lower abdomen and mild increase in body 
temperature.
 
Naa 
Niram 
Pallor 
Depending on body constitution it may be black (vatham), red or yellow 
(pitham), whitish (kapham) or mixed colour (thonthanaadi) 
 
Mozhi Vizhi 
Normal vocal resonance present Conjunctival pallor present, due to menstrual 
blood loss (Anemia)  
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Malam 
Normal bowel habit 
 
Moothiram 
Neerkuri 
“nVf<KlixqvkLl<!nuqOviklkib<!!
n0gz<!nzv<kz<!ngizU,e<!kuqv<f<kpx<!!
Gx<xtuVf<kq!dxr<gq!jugjx!!
Ncg<gzsk<!kiuqOb!giK!ohb<!!
okiVL%v<k<kg<!gjzg<Gm<hM!fQvqe<!!
fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe”!!
.Okvi<!fQi<g<Gxq!ofb<g<Gxq!F~z<!
Urine analysis is done according to five parameters 
1. Niram 
2. Manam 
3. Nurai 
4. Edai 
5. Enjal 
 
In Raktha Soorai Vaayu, 
Niram  : The colour of urine exists in both straw colour & yellow  
Manam: No abnormal smell seen 
Nurai, Edai, Enjal : All the three parameters were normal Neikuri: 
 
In Ratha Soorai Vaayu, neikuri shows mostly Kaphaneer, Pithaneer and 
Vathaneer are less common in thisdisease. 
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3.4 MODERN ASPECT 
PHYSIOLOGY OF FEMALE REPRODUCTIVE SYSTEM 
The Reproductive Cycle 
The female reproductive cycle is the process of producing an ovum and 
readying the uterus to receive a fertilized ovum to begin pregnancy. If an ovum is 
produced but not fertilized and implanted in the uterine wall, the reproductive cycle 
resets itself through menstruation. The entire reproductive cycle takes about 28 days 
on average, but may be as short as 24 days or as long as 36 days for some women. 
 
Oogenesis and Ovulation 
Under the influence of follicle stimulating hormone (FSH), and luteinizing 
hormone (LH), the ovaries produce a mature ovum in a process known as ovulation. 
By about 14 days into the reproductive cycle, an oocyte reaches maturity and is 
released as an ovum. Although the ovaries begin to mature many oocytes each month, 
usually only one ovum per cycle is released. 
 
Fertilization 
Once the mature ovum is released from the ovary, the fimbriae catch the egg 
and direct it down the fallopian tube to the uterus. It takes about a week for the ovum 
to travel to the uterus. If sperm are able to reach and penetrate the ovum, the ovum 
becomes a fertilized zygote containing a full complement of DNA. After a two-week 
period of rapid cell division known as the germinal period of development, the zygote 
forms an embryo. The embryo will then implant itself into the uterine wall and 
develop there during pregnancy. 
 
 
Menstruation 
While the ovum matures and travels through the fallopian tube, the 
endometrium grows and develops in preparation for the embryo. If the ovum is not 
fertilized in time or if it fails to implant into the endometrium, the arteries of the 
uterus constrict to cut off blood flow to the endometrium. The lack of blood flow 
causes cell death in the endometrium and the eventual shedding of tissue in a process 
known as menstruation. In a normal menstrual cycle, this shedding begins around day 
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28 and continues into the first few days of the new reproductivecycle. 
 
POLYCYSTIC OVARIAN SYNDROME 
Poly Cystic Ovarian Syndrome (PCOS) is the most common endocrine 
disorder in women of reproductive age group, affecting 5 to 10% of women 
exhibiting, the full blown syndrome of hyperandrogenism, chronic an ovulation and 
polycystic ovaries. Chronic anovulation accompanied by hyperandrogenism and 
clinical manifestations including hirsutism, acne, elevated testosterone and 
androstenedione, and frequently but not always obesity is seen in PCOS. This disease 
was discovered by and named as Stein-Leventhal syndrome in 1935. 
 
 
 
INCIDENCE 
Approximately 75% of anovulatory women of any cause have polycystic 
ovaries and 20 to 25% of women with normal ovulation demonstrate ultrasound 
findings typical of polycystic ovaries. Current incidence of PCOS (5-6%) is fast 
increasing lately due to change in the lifestyle and stress. It is also becoming a 
common problem amongst adolescents, developing soon after puberty. Amongst 
infertile women, about 20% is attributed to anovulation caused by PCOS. Some of the 
women who develop cardiovascular disease, hypertension, endometrial cancer and 
type 2 diabetes later in life appear to have suffered from PCOS in earlier years 
25 
 
AETIOLOGY 
PCOS has been attributed to several causes including change in lifestyle, diet 
and stress. Initially, the ovaries were thought to set the changes in the endocrine 
pattern. Genetic and familial environment factors (autosomal dominant inherited 
factor) were added as aetiological factors in the development of PCOS. The 
environment factor may function in utero or in early adolescent life, manifesting 
clinically a few years later as PCOS. CYP21 gene mutation has been discovered in this 
connection. Familial occurrence has also been reported. 
 
PATHOPHYSIOLOGY 
When compared with levels found in normal women, patients with persistent 
anovulation have higher mean concentration of LH, but low or low normal levels of 
FSH. The elevated LH levels are partly due to increased sensitivity of the pituitary to 
gonadotropic releasing hormone stimulation. Because the FSH levels are not totally 
depressed, new follicular growth is continuously stimulated, but not to the point of 
full maturation and ovulation, and they are in the form of multiple follicular cysts 2 to 
10mm in diameter. These follicles are surrounded by hyperplastic theca cells, often 
luteinized in response to high LH levels. As various follicles undergo atresia, they are 
immediately replaced by new follicles of similar limited growthpotential. 
 
Poly Cystic Ovarian Syndrome may set in early adolescent life, but clinically 
manifest in the reproductive age with long-term implication of diabetes, hypertension, 
hyperlipidaemia and cardiovascular disease, this cluster of disorders is known as, X 
syndrome. 
Endocrinology changes are as follows: 
1. Estrone / E2 levelrises. 
2. LH level is raised over 10IU/ml 
FSH level remains normal, but FSH/LH ratio falls. 
3. SHBG level falls due tohyperandrogenism 
4. Testosterone and epiandrostenedione levels rise. 
Testosterone >2 ng/ml, free T >2.2 pg/ml (normal level 0.2-0.8 ng/ml) Normal 
androstenedione level is 1.3-1.5 ng/ml. 
DHEA >700 ng/ml suggests adrenal tumor. 
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5. Prolactin is mildly raised in 15%cases 
6. Fasting insulin is more than 10 IU/ml inPCOS 
7. Thyroid function tests may be abnormal(hypothyroidism) 
8. 17 –α- hydroxyprogesterone in the follicular phase >300 ng/dl suggests 
adrenal hyperplasia due to 21 hydroxylasedeficiency. 
 
Insulin and the mechanism of anovulation in Poly Cystic Ovarian Syndrome 
There is growing evidence that hyperinsulinemia may stimulate P 450c 17 
enzyme resulting in hyperandrogenism. P 450c 17 is the key enzyme that regulates 
androgen synthesis. 
 
The characteristic feature of anovulation in PCOS is the arrest of growth of 
antral follicles after reaching a diameter between 5 and 8 mm. This may be caused by 
premature activation of LH. It is well known that the syndrome is clustered in 
families. The sister of the women with PCOS in such a family has a 50% risk of 
PCOS compared with a population prevalence of only 5 to 10%. There is evidence 
from family studies to support a genetic predisposition to develop PCOS and insulin 
resistance that seem to co-exist in thissyndrome. 
 
Role of Hyperinsulinemia in the pathogenesis ofPCOS 
Obesity, genetic predisposition and insulin receptor disorders lead to insulin 
resistance. Insulin resistance leads to abnormal glucose tolerance raising the blood 
sugar, and hyperinsulinemia. This hyperinsulinemia acts on the liver and reduces 
SHBG (sex hormone binding globulin) and also increases IGF-1 (insulin like growth 
factor -1). Reduction of SHBG increases the testosterone, whereas the increased IGF- 
1 will cause increased androgen production from ovaries. Hyperinsulinemia itself 
causes the theca cell hyperplasia and increasedandrogens. 
 
Considering these clinical observations and in vivo/in vitro studies, it was 
proposed that hyperinsulinemia and hyperandrogenism, regardless of which is the 
primary event, is connected to PCOS. 
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Hyperandrogenism in PCOS 
Androgens are important contributors in the pathophysiology of PCOS. In the 
ovary the characteristic morphology of PCOS is closely related to serum androgen 
levels. Recruitment and growth of early follicles is stimulated by androgens, followed 
by a growth arrest at a diameter between 3 and 5 mm. Elevated intrafollicular 
androgen concentrations are held responsible for the succeeding follicular atresia. The 
ability of progesterone to slow down the frequency of the GnRH pulse is reduced in 
hyperandrogenic patients. An accelerated GnRH pulse increases the secretion of 
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luteinzing hormone (LH) while reducing the secretion of follicle stimulating 
hormone. Elevated LH levels stimulate theca-cell-mediated androgen synthesis, 
further increasing hyper androgenism. In such a state, the aromatase activity is 
dependent on FSH, which is not sufficient to convert excess androgens into estrogens. 
Androgen excess has been postulated to be an in vivo environmental factor that 
contributes to insulin resistance in the adipose cells and skeletal muscle of women 
with PCOS. 
 
OBESITY AND PCOS 
More than 50% of women with PCOS are overweight or obese. In comparison 
to lean women with PCOS, obese women with PCOS have a higher prevalence of 
menstrual disorders and infertility. They are more likely to be hirsute, and have lower 
SHBG levels, leading to higher serum concentrations of free testosterone. They are 
also less likely to respond to induction of ovulation. Obesity is defined in forms of an 
increased body mass index (BMI) or an increase waist to hip ratio(WHR). 
 
Weight in Kilogram BMI =Height in m2 
 
Underweight = < 19.9 Kg/m2 Normal = 20-24.9 Kg/m2 Overweight = 25-29.9 
Kg/m2 Obese = > 30 Kg/m2 
 
If the WHR is more than 0.82 then the patients are considered as obese. 
Adipose tissue plays an important role in steroid production and metabolism. Hence, 
it influences the hyperestrogenic state in PCOS and its associated menstrual and 
reproductivedysfunction. 
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LEPTIN 
Leptin, an important adipose derived hormone plays a key role in regulating 
energy intake and energy expenditure, appetite, and metabolism. The Ob (Lep) gene 
(Ob for obese, Lep for leptin) is located on chromosome 7. Leptin binds to the 
ventromedial nucleus of the hypothalamus, known as the “appetite center”. Leptin 
signals to the brain that the body has had enough to eat (satiety). A very small group 
of people possess homozygous mutations for the leptin gene, which leads to a 
constant desire for food, resulting in severe obesity. Although leptin is a circulating 
signal that reduces appetite, in general, obese individuals have an unusually high 
circulating concentration of leptin. They are proposed to be resistant to the effects of 
leptin. The high and sustained concentrations of leptin from the enlarged adipose 
stores result in leptindesensitization. 
 
GHRELIN 
Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the 
stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels 
increases before meals and decrease after meals. It is considered the counterpart of 
the hormone leptin, which induces satiation. Women with PCOS are less satiated after 
a meal compared to normal women. The ghrelin levels of the PCOS patients do not 
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decline after meals to the same extent as control women. 
ANTI-MULLERIAN HORMONE (AMH) AND PCOS 
Anti-Mullerian hormone (AMH), a member of the transforming growth 
factor- β superfamily that includes inhibin and activin, is derived specifically from the 
granulose cells of early developing pre-antral and antral follicles. AMH inhibits the 
initiation of growth of primordial follicle and is reported to act on the follicle cohort 
preventing multiple selection of dominant follicles. There is evidence that abnormal, 
local (follicle-to-follicle) signaling of anti-Mullerian hormone may play a part in 
disordered folliculogenesis in PCOS. It is postulated that the AMH excess is involved 
in the lack of FSH-induced aromatase activity, which characterizes the follicular 
arrest of PCOS. Alternatively, an endocrine action of AMH is suggested since there is 
a 3-4 fold increase in the circulating AMH levels in PCOS patients compared to 
normalwomen. 
 
CLINICAL FEATURES 
An ovarian follicular cyst is usually asymptomatic and unilocular (simple) and 
can reach 15 cm in diameter. It usually regresses during the subsequent menstrual 
cycles. In general, a lutein cyst is apt to be smaller but more firm or even solid in 
consistency and is more likely to cause pain or signs of peritoneal irritation. Because 
it may continue to produce progesterone, it is also more likely to cause delayed 
menses. On occasion, a functional ovarian cyst may undergo torsion or may rupture, 
which may produce acute lower abdominal pain and tenderness and significant 
hemoperitoneum. 
• Hirsutism 
• Oligomenorrhoea 
• Obesity 
• USG showing - Subscapularcysts 
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DIAGNOSIS 
The diagnosis of PCOS is usually made on the basis of a combination of 
clinical, ultrasonographic and biochemical criteria. A woman presenting with 
oligomenorrhoea is likely to have the problem of PCOS if she has one or more of 
these three features: polycystic ovaries on ultrasound, hirsutism and 
hyperandrogenemia. Many women have high LH, although normal LH do not rule out 
thediagnosis. 
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In its fully developed form, PCOS is characterized by menstrual 
abnormalities, hirsutism, obesity, hyperandrogenemia, elevated plasma luteinizing 
hormone (LH) and ultrasonographic evidence of polycystic ovaries. However, thin 
women can also have the problem. Ultrasonographically, there should be more than 
10 cysts 2 to 8 mm indiameter, scattered either around or through an echodense, 
thickened centralstroma. 
Indeed many women with polycystic ovaries detected by sonography do not 
have symptoms of the PCOS. Ovarian morphology appears to be the most sensitive 
marker for the PCOS compared with the classic endocrine features of a raised serum 
LH and / or testosterone concentration. 
 
MANAGEMENT 
• To cure a woman with menstrualdisorders 
• To treathirsutism 
• To treatinfertility 
• To prevent long-term effects of X syndrome in laterlife. 
• The treatment therefore is catered to the requirement of thewoman. 
 
Weight Loss 
Although obesity is not a prerequisite for the diagnosis of PCOS, it is a 
common feature. Almost 50% of women with PCOS have an android type of 
phenotype characterized by waist: hip ratio greater than 0.85(9). Obesity may induce 
hyperandrogenism by increasing the production of androgens, reducing sex hormone 
binding globulin levels (SHBG), thereby increasing free testosterone levels causing 
hyperestrogenemia. This causes pulsatile LH secretion and/or insulin resistance and 
therefore, insulin secretion which could amplify the LH dependent regulatory 
mechanisms that regulate ovarian androgen secretion. 
Increase of LH can cause a vicious cycle of hyperandrogenemia and follicular 
atresia. Even moderate obesity (BMI > 27 kg/m2) is associated with a reduced chance 
of ovulation. Obese women with PCOS (BMI > 30 kg/m2) should therefore be 
encouraged profile and a likelihood of ovulation and healthy pregnancy. 
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Insulin sensitizing agents 
Improving the action of insulin is a relatively new concept in therapy. It is 
demonstrated that reduction of hyperandrogenism in women with PCOS may be 
achieved by interventions which improve insulin sensitivity and reduce circulating 
insulin. Such measures might include, but are not limited to weight loss, dietary 
modifications and insulin sensitizing agents like Metformin. 
 
Diet 
Reducing the caloric intake with reduced glycemic load may be beneficial in 
alleviating hyper-insulinemia and its metabolic consequences. It is recommended that 
obese women with PCOS should reduce the caloric intake by 500 Kcal/day with less 
carbohydrate, a diet which will help them to shed 5% of their weight. 
 
Exercise 
Insufficient physical activity may contribute to obesity in women with PCOS. 
Any weight loss regimen should include regular physical activity to maintain weight 
reduction in the long term. 
 
Life style 
Cigarette smoking should be abandoned. It lowers E2 level and raises DHEA 
and androgen level. Hormones to control menstruation are: 
• Oral combined pills(OC) 
• OC and cyproterone acetate. Oestrogen suppresses androgens and adrenal 
hormones (DHEA). It raises the secretion of SHBG in the liver, which binds 
with testosterone, thus reduces free testosterone. It also suppressesLH. 
• Progesterone may be required to induce menstruation in amenorrhoeic woman 
prior to initiating hormonal cyclicaltherapy. 
• OC with cyproterone is prescribed if the woman hashirsutism. 
 
Hirsutism 
Anti – androgens are used. Dexamethasone (0.5 mg) at bedtime reduces 
androgen production, and is used in some infertile women with clomiphene. 
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Infertility 
Clomiphene is the first line of treatment if PCOS woman is to be treated for 
infertility. 
 
Ovulation Induction 
Women with PCOS belong to WHO group II of anovulatory patients and will 
respond to oral agents such as clomiphene citrate (CC), insulin sensitizers and 
aromatase inhibitors. A few of them will require ovulation induction with 
gonadotropins and some may benefit from assisted reproductive technologies. 
 
Surgery 
Surgery is reserved for those in whom 
• Medical therapyfails 
• Hyperstimulationoccurs 
• Infertilewomen 
• Previous pregnancylosses 
Surgery comprises laparoscopic drilling or puncture of not more than four cysts in 
each ovary either by laser or by unipolar electrocautery. 
 
Prevention 
With the knowledge that PCOS has long-term adverse effects (three fold) on 
health of the woman, such as diabetes, hypertension, cardiovascular disease and 
hyperlipidaemia, endometrial cancer, it is now suggested that PCOS should be 
adequately treated at the earliest. This woman should be observed for these ailments 
in later life. Obesity in adolescents needs to be avoided and corrected. Lifestyle 
changes should be recommended. It is suggested that in utero malnutrition results in 
intrauterine growth – retarded baby which develops PCOD and X syndrome in later 
life. This implies that pregnancy should be managed well to maintain a good health of 
the individual 
 
 
. 
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CHAPTER-IV 
MATERIALS & METHODS  
STUDY AREA AND SETTING   
The study period was covered from June 2017 to July 2019 at the Govt. 
Siddha Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil 
Nadu. All procedures were carried out before getting the permission from Institutional 
Ethical Committee.  
 
STUDY DESIGN 
The study design is a prospective open labeled non-randomized Phase-II 
clinical trial of 40 Raktha soorai vaayu (Polycystic ovarian syndrome) subjects. The  
selected subjects were newly diagnosed or already diagnosed as PCOS patients with 
or without taking treatment.  A written informed consent form was recruited in the 
study. The purpose of the study was explained to the patients before administration of 
trial drug. The patients’ basic information, life style and siddha parameters were 
recorded before starting the treatment.   
 
The total number of 40 female patients and aged ranging from 18 to 45 were 
taken for this study. The selected patients were treated with the trial drug for the entire 
of the study period (60 days).  
 
SELECTION OF PATIENTS 
The criteria for selection of patients are given below (3.3.1). Screening is done 
before starting the treatment.  
Detailed personal history, family history, occupation, habits, clinical 
symptoms, medical history, and the duration of illness were recorded in all patients ( 
proforma annexed). 
 
Inclusion Criteria 
The parameters for the selection were insidious, 
Age: 18 – 45years 
Marital status: Married / Unmarried 
 Patient having the symptoms of irregular menstruation (Kuruthi migunthu 
vizhuthal or Kuruthi veliahathiruthal) 
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Oligomenorrhoea (or) Amenorrhoea (or)Dysmenorrhoea 
Patient willing to take USG pelvis 
Patient willing to undergo routine bloodinvestigation 
USG pelvis showing polycystic ovarianchanges 
Patient willing to participate in trial and signing in consentform 
Increased vathanaadi 
Exclusion criteria  
H/O systemic hypertension 
H/O Type 2 diabetes mellitus 
H/O Cardiac diseases 
H/O liver diseases 
H/O other uterine disorders 
Auto Immune disease 
Pregnancy and lactation 
Known H/O thyroid dysfunction 
Hyper prolactinemia 
Androgen secretingneoplasms 
Other pituitary or adrenal disorders 
Sanninilai 
 
Withdrawal Criteria: 
Intolerance to the drug and development of adverse reactions during the drug 
trial. 
Poor patient compliance &defaulters 
Patients turned unwilling to continue in the course of clinicaltrial 
Occurrence of any seriousillness 
Evaluation of clinical parameters 
 
Patients are evaluated clinically using following parameters 
History taking 
Clinical assessment 
Investigation of blood andurine 
Specific investigation assessments based on siddha system 
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I. History taking 
Age, occupation, previous illness, family history, personal habits were recorded in the 
proforma of every patients. 
 
II. Clinical assessment 
Irregular menstruation 
Amenorrhoea 
Oligomenorrhoea 
Menorrhagia 
Weightgain 
Infertility 
Acanthosis nigricans 
Hirsutism 
Acne 
Androgenichairloss 
BMI 
Waist hipratio 
 
III. INVESTIGATIONS 
Blood 
TC 
DC 
ESR 
Hb 
Sugar (fasting) 
Urea 
Creatinine 
Serumcholesterol 
 
Urine 
Albumin 
Sugar 
Deposits 
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IV.   Specific investigations 
USG – abdomen andpelvis 
 
Diagnosis 
The Siddha diagnostic procedures were included this study, which is,                  
Poriyal Arithal 
Pulanal Arithal 
Vinathal 
Mukkutra nilaigal 
Envagai thervugal 
Nilam 
Kaalam & Udal kattugal 
 
Investigations 
Blood  - Complete blood analysis TC, DC, Hb, TRBC, ESR, 
 Routine Urine Analysis - Albumin, Sugar, Deposits, 
 Stools- for Ova, Cyst and Occult blood were also done. 
 Biochemical Analysis- Serum Cholesterol, Blood Sugar, Blood urea are 
carried out before the treatment and at the time of discharge. 
The Lab investigations were carried out before and after administration of trial 
drug.  
 
TREATMENT 
Preparation of Trial Medicine (Annexure-I (A) & I (B)) 
The herbal preparation of KARUNJCHIRAKAM CHOORANAM was selected from 
the classical siddha literature,  
Reference: “GUNAPADAM MOOLIGAI  VAGUPPU PART-I”- Page No:463-464 
Author: K.S.MURUGESA MUDHALIYAR 
 
Collection and authentication of Trial Medicine (Annexure-I): 
The Nigella sativa Seeds was collected fromthe Nagar kovil based siddha 
medical shop. It was identified and authenticated by the medicinal botanist 
Dr.S.Sutha, Msc., M.Ed.,Ph.D., Associate Professor, Department Of Medicinal 
Botany at Government Siddha Medical College and Hospital, Palayamkottai. 
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Purification of seeds  and preparation of the medicine was executed in the P.G 
Gunapadam Practical lab of Govt. siddha medical college, Palayamkottai.. The 
specimen sample of the Seeds would be preserved in PG Gunapadam department 
individually for future reference. 
 
Preclinical Analysis of Trial Medicine 
All the preclinical studies of the study drug which includes bio-chemical and 
pharmacological studies were carried out and results were cross checked before 
starting the treatment. The bio-chemical analysis was done in Dept. of Biochemistry, 
GSMCH, Palyamkottai. (Annexure-III ). 
The pharmacological activities- Anti hyperglycemic, Anti hyperlipidemic 
activity, Acute and sub-acute toxicity, Phytochemical activitity,hormonal study were 
carried out in this study. (Annexure-IV) studies were done in K.M. College of 
Pharmacy, Madurai -625107.  
 
Ethical Review 
 The study was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and obtained prior approvals before 
start of the trial from the Institutional Ethical Committee of GSMCH, Palayamkottai 
(GSMC-IV-IEC/2017/Br-I/01/29.05.2017) and & Institutional Animal Ethical 
Committee (IAEC) (approval number is 321611001/KMCP/27/2018). The study was 
registered in Clinical Trials Registry. 
 
Study Enrolment   
An open labeled non-randomized phase II clinical trial on “Raktha Soorai 
Vaayu” was conducted in Government Siddha Medical College and Hospital, 
Palayamkottai, Tirunelveli. Totally forty cases were selected. 20 patients were treated 
as OP cases remaining 20 patients as IP cases. The clinical signs and symptoms of 
“Raktha Soorai Vaayu”of different ages were selected and studied under the 
guidance of the professor, reader and lecturer of P.G. Pothu Maruthuvam Department. 
Participants were informed in Tamil language, regarding the trial, the expected 
benefits and their right to opt-out of trial at any time without prejudice.  Informed 
written consent was obtained from each participant, prior to her inclusion into the 
trial.  
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Patients were advised to withdraw in the conditions such as intolerance to the 
drug, development of any serious adverse effects during the trial, patients turned 
unwilling to continue in the course of clinical trial, poor compliance, any other acute 
illness which needs rescue medication and to follow regular diet schedule.The 
subjects with history of treatment with other drugs and serious medical or 
psychological condition are excluded from the study.   
 
During the visit, body weight, blood pressure, cardiovascularand respiratory 
system were clinically recorded. During the treatment if any adverse reaction or side 
effects  occurs,  it was to inform the pharmacovigilence committee. At the end of the 
study period, all the patients were instructed to follow diet. They were also advised to 
pursue the further treatment in the PG, Pothu Maruthuvam OP for the follow up study. 
 
Statistical Analysis  
All data were analysed using the SPSS 20.0 (IBM). Data were expressed as 
means and standard deviation. The significance of the difference between the means 
of the baseline and the final examinations was tested using the paired “t” test. A 
probability value of <0.05 was considered to be statistically significant. 
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CHAPTER-V 
RESULTS AND OBSERVATIONS 
5.1 PRE CLINICAL STUDY 
BIO-CHEMICAL ANALYSIS OF KARUNJCHIRAKAM CHOORANAM 
Preparation of the extract: 
5gms of the drug was weighed accurately and placed in a 250ml clean beaker 
then 50ml of distilled water is added and dissolved well. Then it is boiled well for 
about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is 
made to 100ml with distilled water. This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO. EXPERIMENT OBSERVATION INFERENCE 
1. TEST FOR CALCIUM 
2ml of the above prepared 
extract is taken in a clean test 
tube. To this add 2ml of 4% 
Ammonium oxalate solution 
 
A white precipitate 
is formed 
 
Presence of 
Calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 
5% Barium chloride solution. 
 
A white precipitate 
is Formed 
 
Presence of 
Sulphate 
3. TEST FOR CHLORIDE 
The extract is treated with silver 
nitrate Solution 
 
A white precipitate 
is Formed 
 
Presence of 
Chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
 
No brisk 
effervessence is 
Formed 
 
Absence of 
Carbonate 
5. TEST FOR STARCH 
The extract is added with weak 
iodine Solution 
 
No Blue colour is 
Formed 
 
Absence of 
Starch 
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6. TEST FOR FERRIC IRON 
The extract is acidified with 
Glacial acetic acid and 
potassium ferro cyanide. 
 
No blue colour is 
Formed 
 
Absence of ferric 
Iron 
7. TEST FOR FERROUS IRON 
The extract is treated with 
concentrated Nitric acid and 
Ammonium thiocyanate 
Solution 
 
Blood red colour is 
Formed 
 
Presence of 
ferrous iron 
8. TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium 
Molybdate and concentrated 
nitric acid 
 
No Yellow 
precipitate is 
Formed 
 
Absence of 
Phosphate 
9. TEST FOR ALBUMIN 
The extract is treated with 
Esbachs Reagent 
 
No yellow 
precipitate is 
formed 
 
Absence of 
Albumin 
10. TEST FOR TANNIC ACID 
The extract is treated with ferric 
chloride. 
 
No blue black 
precipitate is 
formed 
 
Absence of 
tannic acid 
11. TEST FOR UNSATURATION 
Potassium permanganate 
solution is added to the extract 
 
It doesnot get 
decolourised 
 
Absence of 
Unsaturated 
Compound 
12. TEST FOR THE REDUCING 
SUGAR 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and add 8-10 drops of 
the extract and again boil it for 
2 minutes. 
 
 
No colour change 
Occurs 
 
 
Absence of 
reducing sugar 
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13. TEST FOR AMINO ACID 
One or two drops of the extract 
is placed on a filter paper and 
dried well. After drying, 1% 
Ninhydrin is sprayed over the 
same and dried it well. 
 
Violet colour is 
Formed 
 
Presence of 
amino acid 
14. TEST FOR ZINC 
The extract is treated with 
Potassium Ferrocyanide. 
 
No white 
precipitate 
is formed 
 
Absence of zinc 
 
Inference 
Indicates  presence of calcium,Sulphate, Cholride,Ferrous iron and  Amino 
acid. 
 
PHYTOCHEMICAL ANALYSIS 
Result of Qualitative phytochemical analysis of KARUNJCHIRAKAM 
CHOORANAM 
 OBSERVATION INFERENCE 
Alkaloids A white or creamy 
precipitate indicates that the 
test as positive  
Presence of alkaloids 
Carbohydrates  Appearance of brown ring 
at the junction of 2 layers 
shows the presence of 
carbohydrates 37 
Presence of carbohydrates 
Glycosides  Appearance of pink to red 
color shows the presence of 
glycosides and aglyeones 
Presence of glycosides 
Phytosterols Appearance OF BLUISH 
GREEN COLOR SHOWS 
THE PRESENCE OF 
PHYTOSTEROLS 
Presence of phytosterols 
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Saponins Absence of the foam 
formation shows the devoid  
of saponins  
Absence of saponins 
Phenolic compounds and 
tannins 
a)dilute ferric chioride 
solution (5%)gives a dark 
green colour.                      
b)10%agulous potassium 
dicaromate solution gives 
yellowish brown precipitate 
.c)10% leads aletate 
solution gives a white 
precipitate. 
 
Protein and free amino 
acids 
A white precipitate 
indicates the presence of 
protein. A characteristicnn 
purple color indicates the 
presence of amino acids  
Presence of protein, free 
amino acids and free 
amono acids 
Flavanoids Appearance of magenta 
color shows the presence of 
flavanoids 
Presence of flavanoids  
Lignin Appearance red 
color,which shows lignin is 
present 
Presence of lignin 
Fixed oils and fats Soap formation indicates 
the presence of fats and 
fixed oils 
Absence of fixed oil and 
fats         
 
The above Table no The qualitative phytochemical analysis was resulted in the 
presence of Alkaloids ,Carbohydrates ,Glycosides ,Phytosterols ,Flavanoids ,Tannins 
,Proteins  and Lignin. 
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ANTI – MICROBIAL ANALYSIS OF KARUNJCHIRAKAM  CHOORANAM: 
 
 
 
Keys 
PC - Positive Control (Streptomycin) 
NC - Negative Control 
-   - No Zone 
Mm - Millimetre 
G+ - Gram Positive Organism 
G- - Gram Negative Organism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
Code 
Bacteria  Strains Name 
Staphylococcus 
aureus (G+) 
Streptococcus 
mutans (G+) 
Bacillus 
subtilis(G+) 
Klebsilla 
pneumonia 
(G-) 
E – coli 
(G-) 
KJC 11 8 9 11 14 
PC 24 11 24 20 17 
NC - - - - - 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Staphylococcus aureus Fig.2 Streptococcus Mutans 
Fig.3 Bacillus Subtilis 
Fig.5 E-Coli 
Fig.4 Klebsiella Pnaumoniae 
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PHARMACOLOGICAL ACTIVITY 
Effect of siddha formulation karunjchirakam  chooranam on female wistar rats 
with estradiol valerate induced polycystic ovarian syndrome 
Induction of PCOS in the Animals 
Thirty adult virgin Wistar rats of approximately 10-12 weeks of 
age with regular 4-5 day oestruscycles as assessed by vaginal smear, were 
used for the study(8). Six of the rats were kept as controls, and the others 
were each given intramuscular injection of 4 mg EV in an oily solution 
per rat.(9,10)Vaginal smears were examined daily in all animals. 
Cessation of cyclicity, which was shown by the persistent cornification of 
vaginal smears, was used as a criterion forselection into the PCOS group. 
 
Treatment Protocol     
The rats were allowed to establish PCOS for 30 days.(14) After 30 
days, groups in G4 & G5  were dosed orally by gavage for 15 days,  
whereasrats in the standard group was dosed for 5 days. 
• Group 1 served as the normal control.   
• Group 2 served as the PCOS control. Group 1 and 2 receives 
normal diet and Water.  
• Group 3 served as the positive control, was treated with injection 
Clomiphene citrate at 20 mg/kg body weight, Intra 
peritoneally.(15) 
• Group 4 served as the treatment control, treated with siddha 
formulation karumjeeraga chooranam at 100 mg/kg body weight, 
through orally. 
• Group 5 served as treatment control which was treated with siddha 
formulation karumjeeraga chooranam at 200 mg/kg of body 
weight, through orally. 
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On 16th day, Six animals from each group (Control and PCO) were 
randomly selected and anaesthetised with ether. Blood samples were 
collected by retro orbital puncture, and the serum were used for hormonal 
assays (FSH, LH, estradiol, progesterone andtestosterone). The ovaries 
were excised and weighed, and histopathological examination was 
conducted on the ovaries.  
Table no:1 Effect of siddha formulation karunjchirakam 
chooranamon hormonal level in EV induced PCOS 
 
G1- Normal, G2-Toxic, G3-Standard, G4-Low dose (karunjchirakam  chooranam), G5-
High dose (karunjchirakam chooranam). 
All values expressed as means ± SEM for 6 animal in each group.  
**a- Values are significantly different from  Normal control (G1) at P<0.001 
**b- Values are significantly different from PCOS control (G2) at P<0.001  
*b- Values are significantly different from PCOS control (G2) at P<0.01  
  
There was statistically significant decrease in estradiol levels with 
Estradiol valerate(EV) injection after 30 days (p<0.01). Concurrent 
administration of karunjchirakam chooranam  for 15 days showed 
significant rise in estradiol levels (p<0.01). Animals in Standard group 
also showed significant rise in estradiol levels. ( Table:1) 
 
 
GROUP LH FSH Estradiol TSN PRGSN 
G1 6.10±0.25 8.50±0.30 55.05±2.30 0.30±0.04 14.10±0.75 
G2 11.70±0.68**a 2.52±0.18**a 14.25±0.85**a 0.40±0.06**a 7.08±0.34**a 
G3 5.60±0.30**b 7.28±0.50 45.30±1.78**b 0.32±0.05 12.25±0.40**b 
G4 3.95±0.10**b 6.85±0.54**b 38.10±1.38**b 0.36±0.05**b 10.8±0.75**b 
G5 4.35±0.18**b 6.35±0.60**b 41.15±1.45**b 0.34±0.04**b 11.74±0.88**b 
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Toxic control group i.e treated with estradiol valerate had shown 
significant lowering ofprogesterone. But treatment with karunjchirakam 
chooranam at both doses (100mg/kg and 200mg/kg) along with EV was 
able to increase the progesterone levels(p<0.001)to near normal values 
significantly. Similar results were also observed in standard 
group.(Table:1) 
 
There was   no significant rise in testosterone levels after exposure 
of rats to estradiol valerate (p<0.01) for 30 days.Treatment with 
karunjchirakam  chooranam at two doses 100mg/kg and 200mg/kg for 
15days doesn’t show any significant changes in testosterone levels. 
Similar results were observed after clomiphene treatment.(Table:1) 
 
Effect of siddha formulation karunjchirakam chooranam on ovarian 
morphology 
Table.2  Effect of karunjchirakam chooranam on ovarian 
morphology of PCOS rats 
Dose 
mg.kg 
ovarian 
feature 
Normal 
Toxic 
control 
Std 
control 
Low dose High dose 
Atretic 
follicle 
0.00±0.00 4.68±0.30 1.15±0.05 3.10±0.20**b 0.06±0.01*b 
Cystic 
follicle 
0.00±0.00 10.68±1.40 3.5±0.60 0.00±0.00 0.00±0.00 
Cystic 
follicle 
diameter 
0.00±0.00 86.90±2.38 70.30±2.60 0.00±0.00 0.00±0.00 
Cystic 
follicle 
thickness 
0.00±0.00 42.36±1.90 33.75±2.20 0.00±0.00 0.00±0.00 
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G1- Normal, G2-Toxic, G3-Standard, G4-Low dose (karunjchirakam  chooranam), G5-
High dose (karunjchirakam chooranam). 
All values expressed as means ± SEM for 6 animal in each group. 
**b- Values are significantly different from PCOS control(G2) at P<0.001  
*b- Values are significantly different from PCOS control(G2) at P<0.01 
 
Ovaries of toxic control (Estradiol valerate) group exhibited more 
cystic follicles compared with other groups but these were not evident in 
extract control group. Both the 100mg/kg &200mg/kg showed normal 
follicle at different stage of development.There was evident of arteric 
follicles present in 100mg/kg.The group that received 200 mg/kg showed 
numerous healthy developing follicles.  ( Table:2) 
  
The follicular diameter & thickness of the cysts in PCOS treated 
group were increased whereas it was reduced in standard & extract 
treated groups ( Table:2). 
 
The ovarian weight of EV control group showed a significant 
decrease (p<0.01), when compared with other groups, whereas in treatment 
control  group 100mg/kg &200mg/kg it was restored to near normal values. 
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Anti-hyperglycemiuc effect of siddha formulation karunjchirakam 
chooranam in alloxan induced diabetes rats 
MATERIALS AND METHODS 
Materials: 
Animals : Male albino wistar rats (180-220gm) 
Drugs  : siddha formulation Karunjchirakam  chooranam 
Chemical : Alloxan monohydrate (S. D Fine. Chem. Ltd, Mumbai) 
 
INDUCTION OF DIABETES MELLITUS 
 Diabetes mellitus is induced in wistar rats by single intraperitoneal injection of 
freshly prepared solution of Alloxan monohydrate (150mg/kg BW) in physiological 
saline after overnight fasting for 12hrs.[1] 
 
 Alloxan is commonly used to produce diabetes mellitus in experimental 
animals due to its ability to destroy the β-cells of pancreas possibly by generating the 
excess reactive oxygen species such as H202, 02 and H0-. The development of 
hyperglycemias in rats is confirmed by plasma glucose estimation 72 hrs post alloxan 
injection. The rats with fasting plasma glucose level of 160-220mg/dl were used for 
this experiment. 
 
Experimental procedure:  
 In the experiment a total of 30 rats (24 diabetic surviving rats & 6 normal rats) 
were used. Diabetes was induced in rats 3 days before starting the experiment. The 
rats were divided into 5 groups after the induction of alloxan diabetes. In the 
experiment 6 rats were used in each group. 
 
TREATMENT PROTOCOL 
 Group-I:  (Normal control) consist of normal rats given with 10ml/Kg of 
normal saline, orally. 
 Group-II:  (Toxic control) Diabetic control received 150mg/Kg of Alloxan 
monohydrate through I.P. 
 Group-III:Diabetic control received glipizide at a dose of (10mg/Kg orally) for 
28 days. 
 Group-IV: Diabetic control received siddha formulation Karunjchirakam 
chooranam at a dose of (100mg/Kg orally) for 28 days. 
 Group-V : Diabetic control received siddha formulation Karunjchirakam 
chooranam at a dose of (200mg/Kg orally) for 28 days. 
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METHODOLOGY 
Sample collection: 
After 28 days of treatment, body weight, blood glucose, haemoglobin, 
glycosylated haemoglobin, plasma insulin, total cholesterol, triglycerides, HDL-
cholesterol and phospholipids were determined. Blood was collected from the eyes 
(venous pool) by sino-ocularpuncture. [2] in EDTA coating plasma tubes for the 
estimation of blood parameters. 
 
Table No: 3 Effect of siddha formulation Karunjchirakam  chooranamon initial 
and final body weight and  blood glucose in normal and treated animals. 
 
• Values are expressed as mean ± SEM. 
• Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
• ** (a) Values are significantly different from normal control G1 at P<0.001. 
 ** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
 
 
GROUP 
Body weight (g) Blood 
glucose (mg / 
100ml) 
Initial 
Blood glucose 
(mg / 100ml) 
Initial Final Final 
G1 228 ± 7.20 240± 7.45 90.60 ± 3.40 
92.80 
± 3.85 
G2 234 ± 7.35 178 ± 4.55**(a) 91.80 ± 3.60 
220.50 
± 6.94**(a) 
G3 236 ± 7.38 245 ± 7.50 89.45 ± 4.05 
126.40 
± 4.45**(b) 
G4 225± 7.15 242 ± 7.40 83.60± 3.60 
142.45± 
5.30**(b) 
G5 235 ± 7.36 246 ± 7.54 95.40 ± 3.80 
132.50 
± 4.46**(b) 
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RESULT 
 According Table no: 3 illustrates the levels of initial and final blood glucose, 
and  change in body weight , in normal rat, and treatment control animals in each 
group. The mean body weight of diabetic rats (G2) was significantly decreased as 
compared to normal control rats. The body weight of diabetic  control rats treated 
with siddha formulation Karunjchirakam chooranam at a dose of 100 and 
200mg/kgwas  increased the body weight non-significantly as compared to normal 
control animals. 
 
Fasting blood glucose level was significantly increased 220.50 ± 6.94 in 
diabetic animals as compared to normal animals. However the level of fasting blood 
glucose, returned to near normal range indiabetic rats treated with siddha formulation 
Karunjchirakam  chooranam at a dose of 100 and 200mg/kg. 
 
Table no:4-Effect of siddha formulation Karunjchirakam  chooranam on plasma 
insulin, Hemoglobin & Glycosylated hemoglobin in normal and treated animals. 
GROUPS 
Haemoglobin 
(gm/100ml) 
Glycosylated 
haemoglobin 
HbA1 (%) 
Plasma Insulin 
(µU/ml) 
G1 12.90 ± 1.70 0.48 ± 0.07 38.60 ± 2.86 
G2 6.30 ± 0.85**(a) 0.96 ±0.20**(a) 13.86 ± 1.88**(a) 
G3 14.30 ± 1.44**(b) 0.44 ±0.09**(b) 29.50 ± 2.50**(b) 
G4 12.80 ± 0.90**(b) 0.50 ±0.18**(b) 26.80 ±2.46**(b) 
G5 11.95 ± 1.24**(b) 0.44±0.07**(b) 28.90± 2.80**(b) 
 
•
 
Values are expressed as mean ± SEM. 
•
 
Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
•
 
** (a) Values are significantly different from normal control G1 at P<0.001. 
 ** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
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RESULT 
In table no: 4illustrates the levels oftotal hemoglobin, glycosylated 
hemoglobin and plasma insulin in normal rat and treatment control animals in each 
group. 
The levels of total hemoglobinand plasma insulin levels were decreased 
significantly where as glycosylated heamoglobin levels were increased significantly 
as compared to normal control rats.However the level oftotal hemoglobin, 
glycosylated hemoglobin and plasma insulin,returned to near normal range indiabetic 
rats treated with siddha formulation Karujchirakam chooranam at a dose of 100 and 
200mg/kg 
 
Table No.5-Serum lipids of Normal and experimental groups. 
GROUPS 
Total 
Cholesterol 
(mg/dl) 
Triglyceride 
(mg/dl) 
HDL-C 
(mg/dl) 
Phospholipids 
(mg/dl) 
LDL 
(mg/dl) 
G1 
87.65 ± 
2.65 
94.70 ± 
2.70 
60.45 ± 
1.76 
130.70 ± 
2.45 
14.50± 1.50 
G2 
232.45 ± 
6.85**(a) 
162.45 ± 
4.60**(a) 
31.75 ± 
1.35**(a) 
219.45 ± 
6.40**(a) 
37.75 
± 2.48**(a) 
G3 
122.95 ± 
3.40**(b) 
98.60 ± 
2.62**(b) 
47.85 ± 
1.40 
152.50 ± 
3.85 
28.25 
± 1.95**(b) 
G4 
132.65 ± 
3.75**(b) 
120.85 ± 
2.85**(b) 
40.35 ± 
1.40**(b) 
162.55 ± 
4.05**(b) 
29.15 
± 1.90**(b) 
G5 
126.45 ± 
3.42**(b) 
98.60 ± 
2.65**(b) 
43.70 ± 
1.60**(b) 
159.35 ± 
3.85**(b) 
24.35 
± 1.80**(b) 
 
• Values are expressed as mean ± SEM. 
• Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keul's multiple range tests.   
• ** (a) Values are significantly different from normal control G1 at P<0.001. 
** (b) Values are significantly different from Diabetic control G2 at  P<0.01. 
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RESULT 
Table no: 5 shows the level of serum total cholesterol (TC), triglycerides (TG), 
high density lipoprotein (HDL),Low density lipoprotein(LDL) and phospholipids of 
normal and experimental animals in each group.Total cholesterol, triglycerides, high 
density lipoprotein,Low density lipoprotein(LDL) and phospholipids levels were significantly 
increased, where as HDL-C level was decreased in alloxan induced diabetic rats as compared 
to normal rats. Treatment of  normal and alloxan induced diabetic rats with siddha 
formulation Karumjeeraga chooranam at a dose of 100 and 200mg/kg for 28 days resulted in 
marked decrease in total cholesterol, triglycerides,Low density lipoprotein(LDL) and 
phospholipids levels and increase in HDL-C levels as compared to alloxan induced diabetic 
rats.  
 
Hypolipidemic activity of siddha formulation karunjchirakam  chooranam in 
hyperlipidemic models of wistar albino rats 
Method 
  All the animals were weighed and divided into five groups and each group 
having six rats. 
 In group I, rats were normal control.  
 In group II, fed the cholesterol to the rats at a dose of 400 mg/kg body weight 
for 30 days. 
 In group III, atorvastatin was fed to rats at a dose of 1mg/kg body weight from 
day 15 to 30.[3 
 In group IV, siddha formulation of karumjeeraga chooranam was fed to rats at 
a dose of 100 mg/kg from 15 days to 30 days. 
 In group V, siddha formulation of karumjeeraga chooranam was fed to rats at 
a dose of 200mg/kg body weight from days 15 to day 30.  
 
 At end of study (30 days) all the rats were sacrificed and the blood was 
collected and allowed to clot the blood and serum was obtained using centrifuge 
machine through centrifugation process. The collected serum samples were analysed 
under biochemical and statistical analysis. 
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Table 6: Effect of Siddha Formulation KARUNJCHIRAKAM CHOORANAM in lipid 
Profile. 
GROUPS 
Total 
cholesterol 
(mg/dl) 
Triglyceride 
s (mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
VLDL 
(mg/dl) AI 
LDL/HD
L 
Normal 
Control 
48.65 ± 
1.65 
58.22± 
0.88 
27.48 
± 1.21 
15.25± 
0.78 
32.85 
± 1.15 
0.86 
± 0.50 
0.55 ± 
Cholesterol 
Control 
118.45± 
1.58**(a) 
163.2 ± 
1.72**(a) 
12.85 
±0.66**(a) 
30.95± 
1.30**(a) 
12.12 ± 
0.72**(a) 
8.50± 
1.33**(a) 
2.40 **(a) 
Standard 
Control 
73.55± 
1.35**(b) 
83.25 ± 
1.84**(b) 
22.4 ± 
0.46**(b) 
21.15± 
0.78**(b) 
25.80 ± 
0.76**(b) 
2.35± 
2.33**(b) 
0.94 **(b) 
Treatment 
control 
93.75 ± 
1.20**(b) 
115.26 ± 
1.92**(b) 
18.3 ± 
0.52**(b) 
24.30± 
0.58**(b) 
16.80 ± 
0.45**(b) 
4.40 ± 
1.48**(b) 
1.32**(b) 
Treatment 
control 
84.80 ± 
0.92**(b) 
95.8± 
1.08**(b) 
21.35 ± 
1.30**(b) 
23.26± 
0.74**(b) 
22.28 ± 
0.50**(b) 
3.12 ± 
0.24**(b) 
**(b) 
 
RESULTS AND DISCUSSION 
Table 6 showed that the level of Serum cholesterol, Triglycerides, HDL, LDL 
and VLDL was significantly increased. It was compared to Standard (Group III) and 
Treatment Control groups (Group IV, V). Rats were feed 100 to 200mg/KJC and 
atorvastatin 1mg/kg were treated in Standard control groups (Group III) with both 
doses of siddha formulation and here was significant decrease in cholesterol, The 
TGs, LDL-C, and VLDL and increases HDL-C when compared with cholesterol 
control rats. Table 1 showed the changes of Atherogenic Index and LDL-C / HDL-C 
ratio in control and treated rats. The test results revealed that the cholesterol induction 
significantly affects the cardio vascular risk markers.  
 
Indeed, AI was statistically increased in cholesterol control group 90% 
compared with the values found in their normal control group. Besides there were 
significant further increase of LDL – C / HDL – C ratio appears due to the 
enhancement of LDL – C catabolism through hepatic receptors. Siddha formulation 
Karum jeeraga chooranam showed protective action  against atherogenesis since an 
independent inverse relationship between blood HDL – C levels and cardio vascular 
risk incidence is reported.[5] The possible pharmacological mechanism of this activity 
may result from the enhancement of lecithin cholesteryl acyl transferase (LCAT) and 
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inhibition of Hepatic Triglyceride Lipase (HTL) on HDL which may lead to a rapid 
catabolism of blood lipids through enterohepatic tissues. Siddha formulation Karum 
jeeraga chooranam significantly suppress the elevated blood concentration of TGs. 
This result suggests that the product is able to restore the catabolism of TG. The 
restoration of catabolic mechanism of TGs would be due to an increased stimulation 
of the lipolytic activity of Plasma Lipoprotein Lipase (LPL). 
 
Administration of siddha formulation Karum jeeraga chooranam provides a 
beneficial action on rat lipid metabolism with regard to the reduction of AI. Infect, the 
AI was decreased in all treated groups. Similar results were reported by others when 
studying the hypolipidemic effects of natural products.[10] The administration of 
siddha formulation of KARUNJCHIRAKAM CHOORANAM is significantly 
suppress the higher values of LDL – C / HDL – C ratio showing the beneficial effect 
of this formulation in preventing atherosclerosis incidence. 
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TOXICOLOGICAL ANALYSIS 
Safety studies of Siddha Medicine KARUNJCHIRAKAM 
CHOORANAM in acute and 
Subacute toxicity wistar rat models 
Materials and Methods 
In acute oral toxicity study, Karunjchirakam  chooranam were 
administeredorally initially at the dose of 50 mg/kg/body weight which was 
increasedup to 2000mg/kg/body weight and animals were observed for toxic 
symptomstill 14 days as per the OECD-423 guidelines. 
 
For sub-acute toxicity study, the KARUNJCHIRAKAM CHOORANAMwere 
administeredfor 20 days, with the doses of 50 mg, 100 mg, 200 mg and 400 mg/kg/ 
body weight for different groups. At the end of 20th day, the animals weresacrificed 
and toxicity parameters were assessed. Biochemical analysis onblood samples and 
histo-pathological evaluation of different organs were alsoperformed to assess any 
toxicity. 
 
Result 
In acute toxicity, there was no mortality or morbidity observedin animals 
through the 14-days period following single oral administration at all selected dose 
levels of the Karunjchirakam chooranam (Table-1). The animals did not show any 
changes in the general appearance during the trial.. 
 
 
 
 
 
 
 
Table.1. Acute toxicity study of KARUNJCHIRAKAM CHOORANAM on 
experimental mice. The acute toxicity of KARUNJCHIRAKAM CHOORANAM on 
experimental rats were tested using OECD-423 guidelines, where ST- sign oftoxicity; 
NB- normal behavior; D- died; S- survive. Values are expressedas number of animals 
(n=3). 
 
Dose 
(mg.kg-1) 
Sign of Toxicity 
(ST.NB-1) 
Mortality 
(D.S-1) 
Group I 0 0/3 0/3 
Group II 300 0/3 0/3 
Group III 2000 0/3 0/3 
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SUB-ACUTE TOXICITY STUDIES 
Effect of Karumjeeraga chooranamon body weight changes in rats 
Table.2.The results of  body weight changes in rats 
 
Treatment Day 1 Day 5 Day 10 Day 20 
Control 187.16±6.13 187.45±6.20 196.14 ±6.35 196.74±6.24 
Karumjeeraga 
chooranam 
50 mg.kg-1 
196.30 ±6.4 194.30±6.30 199.25 ±6.70 199.35±6.72* 
Karumjeeraga 
chooranam 
100 mg.kg-1 
187.35 ±5.7 190.30±6.40 197.55±7.10 198.36±6.40* 
Karumjeeraga 
chooranam 
200 mg.kg-1 
196.35±7.2 199.15±6.50 199.90±7.20** 207.41±7.22** 
Karumjeeraga 
chooranam 
400 mg.kg-1 
189.67±6.05 193.15 ±5.60 196.68±6.35** 208.65±7.38** 
 
• groupIanimals(GPI)weretreatedwithnormalsaline(5ml.kg-1) 
• groupIIanimals(GPII)with50 mg.kg-1 of Karumjeeraga chooranam 
• group III animals (GPIII) with 100 mg.kg-1 of Karumjeeraga chooranam 
• group IV animals (GPIV) with 200 mg.kg-1 of Karunjchirakam  chooranam 
• group V animals (GPV) with 400 mg.kg-1 Karunjchirakam chooranam. 
 
 The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V. The statistical analysis was 
carried out using one way ANOVA method, where **P<0.01*P<0.05. 
 
 
 
 
 
62 
 
Effect of Karunjchirakam chooranamon kidney, heart, liver and 
brain in rats 
Table.3Results in Internal organs: 
 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms) 
Control 0.39 ± 0.07 0.69± 0.06 3.35± 0.08 0.70± 0.08 
Karunjchirakam 
chooranam@ 
50 mg.kg-1 
0.40± 0.02 0.85± 0.03 3.47± 0.03 0.73± 0.33 
Karunjchirakam 
chooranam@ 
100mg.kg-1 
0.41± 0.06 0.83± 0.04 3.39±0.06 0.71± 0.22 
Karunjchirakam 
chooranam@ 
200mg.kg-1 
0.40± 0.08 0.78± 0.06 3.37± 0.07 0.78± 0.08 
Karunjchirakam 
chooranam@ 
400 mg.kg-1 
0.39± 0.07 0.79± 0.08 3.39± 0.05 0.80± 0.08 
 
 
Table.3. A study on the effects of Karunjchirakam chooranamon kidney, 
heart, liver and brain of the rats was tested.  
• group I animals (GPI) treated with normal saline (5 ml.kg-1) 
• group II animals (GPII) with 50 mg.kg-1 of Karunjchirakam  chooranam 
• group III animals (GPIII) with 100 mg.kg-1 of Karunjchirakam  chooranam 
• group IV animals (GPIV) with 200 mg.kg-1 of Karunjchirakam  chooranam 
• group V animals (GPV) with 400 mg.kg-1 Karunjchirakam  chooranam. 
The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V. The statistical analysis was 
carried out using one way ANOVA method, where **P<0.01. 
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Effect of Karunjchirakam chooranamon biochemical profiles of rats 
Treatment 
Glucose 
(mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 92.65± 0.62 37.62± 0.56 26.25± 0.45 133.25± 0.55 82.15±1.72 
Karunjchirakam 
chooranam@ 
50 mg.kg-1 
90.50± 0.56 23.85± 0.25* 11.22± 0.23* 173.28± 0.65* 69.59±1.28 
Karunjchirakam 
chooranam@ 
100 mg.kg-1 
89.50± 0.42 26.79± 0.28* 15.47± 0.30* 165.82±0.81* 69.89±1.12 
Karunjchirakam 
chooranam@ 
200 mg.kg-1 
90.30± 0.57** 33.23± 0.32 17.89± 0.40* 184.35± 0.83* 42.65±1.60 
Karunjchirakam 
chooranam@ 
400 mg.kg-1 
86.30± 0.47** 32.83± 0.31 17.28± 0.34* 182.7± 0.87* 46.55±0.86 
 
Table.4. A study on the effect of Karunjchirakam chooranamon biochemical 
parameters such as glucose, cholesterol, triglyceride, HDL and LDL in rats was 
tested. 
• groupI animals(GPI)treatedwithnormalsaline(5ml.kg-1) 
• groupII animals(GPII) with 50 mg.kg-1 of Karunjchirakam  chooranam 
• group III animals (GPIII) with 100 mg.kg-1 of Karunjchirakam  
chooranam 
• group IV animals (GPIV) with 200 mg.kg-1 ofKarunjchirakam  
chooranam 
• group V animals (GPV)with400mg.kg-1of karunjchirakam chooranam. 
 
The values are expressed as mean ±S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V. The statistical analysis was 
carried out using one way ANOVA method, where **P<0.01*P<0.05 
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The effects of Karunjchirakam  chooranamon biochemical 
parameters such as AST, ALT, ALP, TP and Albumin in rats. 
The results are shown in Table.5 
Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 328.10±12.45 71.10± 3.21 253.58± 8.82 69.90± 3.37 39.20±2.49 
Karunjchirakam 
chooranam@50 
mg.kg-1 
317.0±9.55** 69.5± 2.22** 266.15± 2.77** 70.35± 2.35 36.35±2.67 
Karunjchirakam 
chooranam@ 
100 mg.kg-1 
318.8±7.25** 67.6± 3.20** 260.19± 6.76** 80.20± 2.82 38.35±3.08 
Karunjchirakam 
chooranam@ 
200 mg.kg-1 
331.4±7.97 62.4± 2.96 265.00± 5.22 69.25± 3.34 40.25±2.78 
Karunjchirakam 
chooranam@ 
400 mg.kg-1 
323.2± 8.25 64.3± 3.57 269.40± 4.45 74.05± 2.63 39.48±2.75 
 
Table.5. A study on the effects of Karunjchirakam chooranamon 
biochemical parameters such as AST, ALT, ALP, TP and Albumin rats was tested.  
• group I animals (GPI) were treated with normal saline (5ml.kg-1) 
• group II animals (GPII) with 50 mg.kg-1 of HAEBD 
• group III animals (GPIII) with 100 mg.kg-1 of Karunjchirakam  chooranam 
• group IV animals (GPIV) with 200 mg.kg-1 of Karunjchirakam  chooranam 
• group V animals (GPV) with 400 mg.kg-1 Karunjchirakam chooranam  
 
The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V. The statistical analysis was 
carried out using one way ANOVA method, where **P<0.01*P<0.05. 
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Effect of Karunjchirakam  chooranamon haematological parameters 
inrats 
Treatment 
Haemoglobin 
(mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 15.3± 0.30 11.15± 0.02 13.45± 0.05 11.40 ±0.08 
Karunjchirakam 
chooranam@ 
50 mg.kg-1 
16.55± 0.31* 11.45± 0.06* 11.5± 0.01* 11.21 ±0.03 
Karunjchirakam 
chooranam@ 
100 mg.kg-1 
16.35± 0.15* 11.55± 0.02* 10.3± 0.32* 11.27 ±0.20 
Karunjchirakam 
chooranam@ 
200 mg.kg-1 
14.27± 0.20* 10.32± 0.12* 13.4± 0.03* 11.56 ±0.13 
Karunjchirakam 
chooranam@ 
400 mg.kg-1 
15.5± 0.35* 10.46± 0.45* 12.5± 0.13* 11.70 ±0.02 
 
Table.6.. A study on the effect of Karunjchirakam chooranam on 
haematological parameters such as Hb, RBC, WBC, Calcium in rats was tested.  
• group I animals (GPI) treated with normal saline (5 ml.kg1) 
• group II animals (GPII) with 50 mg.kg-1 of Karunjchirakam  chooranam 
• group III animals (GPIII) with 100 mg.kg-1 of Karunjchirakam chooranam 
• group IV animals (GPIV) with 200 mg.kg-1 of Karunjchirakam chooranam 
• group V animals (GPV) with 400 mg.kg-1 Karunjchirakam  chooranam.  
 
The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV and V. The statistical analysis was 
carried out using one way ANOVA method, where *P<0.0 
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5.2CLINICAL STUDY 
1. Ageincidence 
2. Maritalstatus 
3. Parity 
4. Religiondistribution 
5. Distribution of cases byparuvakaalam 
6. Distribution of cases bythinai 
7. Dietaryhabits 
8. Distribution of cases based on incidence ofinfertility 
9. Body built (based onBMI) 
10. Occupationaldistribution 
11. Positive family history for thedisease 
12. Chronicity ofillness 
a) Irregularmenstruation 
b) Infertility 
13. Treatment history other than siddhatreatment 
a) For treatinginfertility 
b) For irregularmenstruation 
14. Thegi 
15. Derangement inmukkutram 
a) Derangement in vathakutram 
b) Derangement in pithakutram 
c) Derangement in kapha kutram 
16. Gnanenthriyaminvolvement 
17. Kanmenthriyaminvolvement 
18. Kosangal 
19. Disturbance in udalthathukkal 
20. Envagaithervu 
a) Naadi 
b) Neikkuri 
21. Before treatmentAssessments: 
a) Intermenstrual period assessmentscore 
b) Duration of bleedingscore 
22. Clinical symptoms before treatment 
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23. Outcome Measurement before and after treatment 
a) Intermenstrual period assessmentscore 
b) Duration of bleedingscore 
24. Clinical symptoms before and after treatment 
25. Changes in USG aftertreatment 
26. Before and after KARUNJCHIRAKAM CHOORANAM intervention 
27. BMI score before and aftertreatment 
28. Waist Hip Ratio Before and AfterTreatment 
29. Case Summary of OutPatient 
30. Case Summary of InPatient 
31. Laboratory Investigations of OutPatients 
32. Laboratory Investigations of InPatients 
 1. AGE INCIDENCE 
Table : 1 Illustrate the distribution of age incidence and its percentage
 
AGE (YEAR) 
OP PATIENTS
NO. OF 
CASES
18-25 7 
26-35 13 
36-45 0 
Total 20 
 
 
FIGURE – 1(AGE INCIDENCE)
 
Among 20 OP cases, 7(35%) cases were in the age group of 18
cases were between 26-35.
Among 20 IP cases, 4(20%) case was between the age group of
case were between 26-35, 14(70%) cases were between 36
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PERCENTAGE 
NO.OF 
CASES 
PERCENTAGE
35% 4 
65% 2 
0 14 
100% 20 
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 2. MARITALSTATUS
Table: 2 Illustrates the distribution of marital status
 
MARITAL 
STATUS 
OP PATIENTS
NO. OF 
CASES
Unmarried 9 
Married 11 
Total 20 
 
 
FIGURE – 2(MARITAL STATUS
 
Among 20 OP cases, 9(45%) were unmarried, 11(55%) were married Among 
20 IP cases, 3(15%) were unmarried, 17(85%) were married.
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 IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
45% 3 15%
55% 17 85%
100% 20 100%
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 3. PARITY 
Table: 3:Distribution of parity
 
 
PARITY 
OP PATIENTS
NO. OF 
CASES
Multiparous - 
Uniparous 2 
Nulliparous 9 
Total 11 
 
 
FIGURE – 3( PARITY)
 
Among in 11 Marrried  OP cases, 2(18.18%) were uniparous and 9(81.81%) 
were nulliparous. Among in17   IP cases, 3(117.64%) were multiparous, 10(58.82%) 
were uniparous and4(23.52%) were nulliparous.
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 IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
- 3 17.64%
18.18% 10 58.82%
81.81% 4 23.52%
100% 17 100%
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 4. RELIGION DISTRIBUTION
Table: 4: Distribution of religion
 
 
RELIGION 
OP PATIENTS
NO. OF 
CASES
Hindu 14 
Christian 2 
Muslim 4 
Total 20 
 
 
FIGURE – 4(RELIGION 
 
Among 20 OP cases, 14(70%) were Hindus, 2(10%) were Christians, 4(20%) 
was Muslim. 
Among 20 IP cases, 19(95%) were Hindus, 1(5%) were Christians, 0(0%) 
wasMuslim. 
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 IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
70% 19 95%
10% 1 5%
20% 0 0%
100% 20 100%
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 5. PARUVA KAALAM (SEASON)
Table: 5: Distribution of 
PARUVAKAALAM
Kaarkaalam (Aug16–Oct 15)
Koothirkaalam (Oct 16–Dec 15)
Munpanikaalam (Dec 16
Pinpanikaalam (Feb 16-Apr 15)
Ilavenilkaalam (Apr 16-Jun 15)
Mudhuvenilkaalam (Jun 16
Total 
 
FIGURE – 5 (PARUVAKAAALAM)SEASON
 
Among 20 OP cases, 8(40%) cases the treatment period was munpanikaalam, 
5(25%) cases it was pinpanikaalam.4(20 ) cases it was ilavenilkaalam , 3(15 )
was Mudhuvenilkaalam. 
Among 20 IP cases, 2(10%) cases it was Koothirkaalam, 8(40%) cases it was 
pinpanikaalam, 8(40%) cases it wasilavenilkaalam.2(10 ) cases it was 
Mudhuvenilkaalam. 
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paruva kaalam (season) 
 
OP PATIENTS IP PATIENTS
NO. OF 
CASES 
% 
NO. OF 
CASES 
 - 0 - 
 - 0 2 
-Feb 15) 8 40% - 
 5 25% 8 
 4 20% 8 
-Aug 15) 3 15% 2 
20 100% 20 
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6.THINAI 
Table: 6: Distribution of thinai 
 
THINAI 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Kurinji 4 20% 3 15% 
Mullai - - - - 
Marutham 14 70% 16 80% 
Neithal 2 10% 1 5% 
Paalai - - - - 
Total 20 100% 20 100% 
 
 
FIGURE – 6( THINAI) 
 
 
Among 20 OP cases, 4(20) cases were from the land Kurinji, 14(70%) cases 
were from the land Marutham, 2(10%) case was from the land Neithal. 
Among 20 IP cases, 3(15%) cases were from the land Kurinji, 16 (80%) were 
from the land Marutham and 1(5%) were from the land Neithal. 
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 7.DIET 
Table: 7: Distribution of Diet
DIET 
OP PATIENTS
NO. OF 
CASES
Vegetarian 2 
Non- 
Vegetarian 
18 
Total 20 
 
 
FIGURE – 7( DIET) 
 
Among 20 OP cases, (10%) were Vegetarian, 18(90%) were Non
Among 20 IP cases, 1(5%) was Vegetarian, 19(95%) were Non
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 IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
10% 1 5%
90% 19 95%
100% 20 100%
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 8. CASE DISTRIBUTION
Table: 8: Distribution of case
CASE 
DISTRIBUTION NO. OF 
CASES
PCOS 
PCOS along with 
infertility 
PCOS in fertile 
women 
Total 
 
 
FIGURE – 8 (CASE DISTRIBUTION)
 
Among 20 OP cases, 9(45%) cases was diagnosed as PCOS, 9(45%) have 
PCOS along with infertility, 2(10%) cases was fertile with PCOS.
Among 20 IP cases, 3(15%) cases were diagnosed as PCOS, 4(20%) cases had 
PCOS along with infertility, 13(65%) cases were diagnosed as 
women. 
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OP PATIENTS IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
9 45% 3 15%
9 45% 4 20%
2 10% 13 65%
20 100% 20 100%
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 9. BODY BUILT 
Table: 9: Distribution of body built
BODY BUILT 
BASED ON BMI NO. OF 
CASES
Under weight 
(below 20) 
Normal weight 
(21-25) 
Over weight (25-
30) 
Obese (>30) 
Total 20
 
 
FIGURE – 9(BODY BUILT)
 
Among 20 OP cases, 2(10%) cases were underweight, 6(30%) cases were 
normal weight, 8(40%) cases were overweight, 4(20%) cases were 
Among 20 IP cases, 8(40%) cases were normal weight, 10(50%) cases were 
overweight, 2(10%) cases were obese.
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 10.OCCUPATIONAL DISTRIBUTION
Table: 10; Distribution of occupation
OCCUPATION NO. OF 
CASES
Employee 
Non-Employee 
Student 
Total 
 
 
FIGURE– 10 (OCCUPATIONAL DISTRIBUTION)
 
Above 20 OP cases, 2(10%) cases were employee, 8(40%) cases were non
employee, 10(50%) cases were students.
Above 20 IP cases, 3(15%) cases were employee, 14(70%) cases were non
employee, 3(15%) case was students.
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OP PATIENTS IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
2 10% 3 15%
8 40% 14 70%
10 50% 3 15%
20 100% 20 100%
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 11.POSITIVE FAMILY HISTORY FOR THEDISEASE
Table: 11: Distribution positive family history
FAMILY 
HISTORY 
FOR THE 
DISEASE 
NO. OF 
CASES
In I degree 
relationship 
2
No positive 
family history 
18
Total 20
 
 
FIGURE – 11(POSITIVE FAMILY HISTORY)
 
Among 20 OP cases, 2(10%) cases have positive family history, 18(90%) 
cases have no relevant familyhistory.
Among 20 IP cases, 19(95%) cases have no positive family history and 1(5%) 
case had positive family history.
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OP PATIENTS IP PATIENTS
 
 
PERCENTAGE 
NO. OF 
CASES PERCENTAGE
 10% 1 5%
 90% 19 95%
 100% 20 100%
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 12. CHRONICITY OF ILLNESS 
Table:12 (a) Irregular Menstruation
CHRONICITY OF 
ILLNESS 
Less than 6 months 
6 months – 1 year 
1 – 2 years 
2 – 5 years 
5 - 10 years 
>10 years 
Total 
 
FIGURE – 12(a)( IRREGULAR MENSTRUATION)
 
Among 20 OP cases, 4(20%) cases were between six months 
cases were between 1- 2 years,
Among 20 IP cases,
cases were between 1–2 year,
 
 
Less than 6 months
6 months – 1 year
1 – 2 years
2 – 5 years
5 - 10 years
>10 years
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OP PATIENTS IP PATIENTS
NO. OF 
CASES 
% NO. OF CASES
- - - 
4 20% 6 
5 25% 6 
11 55% 8 
- - - 
- - - 
20 100% 20 
 
– 1 year, 5(25%) 
 11(55%) cases were between 2 – 5 years. 
 6(30%) cases were between 6 months–1year,
 8(40%) cases were between 2–5 years. 
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 Table: 12 (b) Nulliparous
 
YEAR OF 
INFERTILITY NO. OF 
CASES
1 – 2 years 
3 – 5 years 
6 – 10 years 
Total 
 
FIGURE – 12(b) (NULLIPAROUS )
 
Among 9 OP cases, 4(44.44%) case was nulliparous for 1
cases were for 3-5 years..
Among 4 IP cases, 3(75%) case was nulliparous for 1
cases were for 3-5 years. 
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PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
4 44.44% 3 75%
5 55.55% 1 25%
- - - 
9 100% 4 100%
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 13. TREATING FOR INFERTILITY
Table:13 (a) For treating
VARIOUS 
TREATMENTAL 
HISTORY 
NO. OF 
CASES
Ovulation induction 
Not undergo any 
treatment before 
Total 
 
FIGURE – 13(a) FOR TREATING INFERTILITY
 
Among 9 OP cases, (44.44%) cases had undergone ovulation induction 
treatment, 5(55.55%) case had not undergone anytreatment.
Among 4 OP cases, 2(50%) cases had undergone ovulation induction 
treatment, 2(50%) case had not undergone anytreatment.
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 infertility 
OP PATIENTS IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
4 44.44% 2 50%
5 55.55% 2 50%
9 100% 4 100%
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50%
50%
Not undergo any 
treatment before
Ovulation induction
 
 
 
 
 
 
 Table: 13 (b) FOR IRREGULAR MENSTRUATION
VARIOUS 
TREATMENTAL 
HISTORY 
NO. OF 
CASES
Menstruation 
induction 
Not undergo any 
treatment before 
Total 
 
FIGURE – 13(b )FOR IRREGULAR MENSTRUATION 
 
Among 9 op cases, 5(56%) cases had undergone treatment for 
induction and 4(44%) cases had undergone any treatment before.
Among 4 IP cases,2 (50%) had undergone treatment for menstruation 
induction and 2(50%) had not underwent any treatment
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OP PATIENTS IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
5 56% 2 50%
4 44% 2 50%
9 100% 4 100%
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 14. THEGI 
Table: 14: Distribution of t
 
 
NO. OF 
CASES
Vatha thegi 5
Pitha thegi 3
Kapha thegi 5
Thontha thegi 7
Total 20
 
 
FIGURE – 14(THEGI) 
 
Among 20 OP cases, 5(25%)
5(25%) were kapha thegi and 7(35%) were
Among 20 IP cases, 4(20%) were vatha
were kapha thegi and 8(40%) were thontha
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hegi 
OP PATIENTS IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
 25% 4 
 15% 2 
 25% 6 
 35% 8 
 100% 20 
 were vatha thegi, 3(15%) were pitha
 thontha thegi. 
 thegi, 2(10%) was pitha thegi, 6(30%) 
 thegi. 
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15.DERANGEMENT IN VATHAM 
Table: 15 (a) Distribution of vatham 
CLASSIFICATION  
OF VALI 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Pranan - 0 - O 
Abanan 20 100% 20 100% 
Viyanan 20 100% 20 100% 
Udhanan - 0 - 0 
Samanan 20 100% 20 100% 
Nagan - 0 - 0 
Koorman - 0 - 0 
Kirukaran - 0 - 0 
Devadhathan 16 80% 15 75% 
Danajeyan - 0 - 0 
 
 
 
 
 
 
 
 
 
 
 FIGURE – 15 (a) (DEARRENGEMENT IN V
 
In OP study Abanan was affected in 20 (100%) cases, Viyanan was affected in 
20(100%) cases, Samanan was 
affected in 16 (80%) cases.
In IP study Abanan was affected in 20(100%) cases, Viyanan was affected in 
20(100%) cases, Samanan was affected in 20(100%) cases and Devadhathan was 
affected in 15(75%) cases.
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ATHAM) 
affected in 20(100%) cases, and Devadhathan was 
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15. DERANGEMENT IN PITHA KUTRAM 
Table: 15 (b): Distribution of pitha kutram 
CLASSIFICATION 
OF AZHAL 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Analagam - - - - 
Ranjagam 5 25% 3 15% 
Sathagam - - - - 
Alosagam - - - - 
Prasagam - - - - 
 
 
FIGURE – 15 (b) (DEARRANGEMENT IN PITHA KUTRAM) 
 
 
In OP study, ranjagam was affected in 5 (25%) cases. In IP study, ranjagam 
was affected in 3(15%) cases. 
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15.DERANGEMENTS IN KAPHA KUTRAM 
Table: 15 (c): Distribution of kapha kutram 
CLASSIFICATION 
OF KAPHAM 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Avalambagam - 0 - 0 
Kiletham - 0 - 0 
Pothagam - 0 - 0 
Tharpagam - 0 - 0 
Santhigam 7 35% 6 30% 
 
 
FIGURE – 15(c)(DERANGEMENT IN KAPHA KUTRAM) 
 
 
In OP study santhigam was affected in 7(35%) cases. In IP study santhigam 
was affected in 6(30%) cases. 
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16.DISTRIBUTION IN GNANENTHRIYAM 
Table: 16: Distribution of gnanenthiriyam 
GNANENDRIYAM 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Mei 8 40% 10 50% 
Vai - - - - 
Kan 5 25% 3 15% 
Mooku - - - - 
Sevi - - - - 
 
 
FIGURE – 16 (DISTURBANCES  IN GNANENTHRIYAM) 
 
 
In OP study kan was affected in 5(25%) cases and mei was affected in 8(40%) 
cases. 
  In IP study kan was affected in 5(15%) cases and mei was affected in 10(50%) 
cases
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 17. KANMENTHRIYAM
Table: 17: Distribution of kanmenthriyam
KANMENTHRIYAM 
Kai 
Kaal 
Vaai 
Karuvaai 
Eruvaai 
 
FIGURE- 17 KANMENTHRIYAM INVOLVEMENT
 
In OP study, Karuvaai was affected in 20(100%) cases.
In IP study, Karuvaai was affected in 20(100%) cases 
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OP PATIENTS IP PATIENTS
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
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PERCENTAGE
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18. KOSANGAL 
Table: 18. Distribution of kosangal 
KOSANGAL 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Annamayakosam - - - - 
Pranamayakosam - - - - 
Manomayakosam - - - - 
Vignanamayakosam - - - - 
Ananthamayakosam 20 100% 20% 100% 
 
 
FIGURE – 18  KOSANGAL 
 
 
In OP study Ananthamaya kosam was affected in 20(100%) cases. In IP study 
Ananthamaya kosam was affected in 20(100%) cases. 
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19. DISTURBANCE IN UDALTHATHUKKAL 
Table: 19. Distribution of Udal Thathukkal 
UDAL 
THATHUKKAL 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Saaram - - - - 
Senneer 5 25% 3 15% 
Oon - -  - 
Kozhuppu 11 55% 12 60% 
Enbu - - - - 
Moolai - - - - 
Suronitham 20 100% 20 100% 
 
 
FIGURE – 19 UDAL THATHUKKAL 
 
In OP study, Senneer got affected in 5(25%) cases, Kozhuppu got affected in 
11(55%) cases, and Suronitham got affected in 20 (100%) cases. 
In IP study, Senneer got affected in 3(15%) cases, Kozhuppu got affected in 
12(60%) cases and Suronitham got affected in 20(100%) cases. 
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 20. ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC METHODS) 
Table:20: Distribution of envagai thervugal
ENVAGAI 
THERVU NO. OF 
CASES
Naadi (Thontham) 
 
Vatham 
Naa 
Niram 
Mozhi 
Vizhi 
Sparisam 
Malam 
Moothiram 
 
FIGURE – 20  ENVAGAI THERVUGAL
In OP study, Thondhanaadi was seen in 19(95%) cases, vathanaadi was seen 
in 1(5%) case  
In IP study, Thonthanaadi was seen in 19(95%) cases, vathanaadi was seen in 
1(5%) case  
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OP PATIENTS IP PATIENTS
 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE
19 
 
1 
95% 
 
5% 
19 
 
1 
95%
5%
- - - 
- - - 
- - - 
- - - 
- - - 
- - - 
- - - 
 
5%
0 0 0 0 0 0 0
5%
0 0 0 0 0 0 0
 
 
 
 
 
 
- 
- 
- 
- 
- 
- 
- 
 
OP
IP
93 
 
20. (a) NAADI 
Table: 20 (a): Distribution of Naadi 
 
NAADI 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Vatha pitham 7 35% 6 30% 
Pitha vatham 5 25% 4 20% 
Kapha vatham 7 35% 9 45% 
vatham 1 5% 1 5% 
Total 20 100% 20 100% 
 
FIGURE – 20(a) NAADI 
 
 
In OP study, 7(35%) cases revealed Vathapitha naadi, 5(25%) cases revealed 
Pithavatha naadi, 7(35%) cases revealed Kaphavatha naadi and 1(5%) case revealed 
Vathanaadi. 
In IP study, 6(30%) cases revealed Vathapitha naadi, 4(20%) cases revealed 
Pithavatha naadi, 9(45%) cases revealed Kaphavatha naadi and 1(5%) case revealed 
Vathanaadi. 
Naadi 
45 
50 
40 
30 
20 
10 
0 
35 30 
25 20 35 
5 
5 
Vatha 
pitham 
IP 
OP 
OP 
IP 
Pitha 
vatham Kapha 
vatham Vatham 
94 
 
20.(b)NEIKKURI 
Table: 20 (b): Distribution of Neikkuri 
SPREADING 
PATTERN 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Vatha neer 4 20% 5 25% 
Pitha neer 3 15% 3 15% 
Kapha neer 13 65% 12 60% 
Total 20 100% 20 100% 
 
 
FIGURE – 20(b) NEIKKURI 
 
 
In OP study, 4(20%) cases showed vathaneer pattern, 3(15%) cases showed 
pithaneer pattern and 13(65%) cases showed kaphaneer pattern. 
In IP study, 5(25%) cases showed vathaneer pattern, 3(15%) cases showed 
pithaneer pattern and 12 (60%) cases showed kaphaneer pattern. 
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 20. (a) INTERMENSTRUAL PERIOD ASSESSMENT SCORE
Table.21. (a) Intermenstrual Period Assessment Score
GRADE 
LENGTH OF THE CYCLE
0 28 days 
1 28 – 45 days 
2 45 – 60 days 
3 Above 60 days 
Total 
 
FIGURE – 21 (INTERMENSTRUAL PERIOD ASSESSMENT SCORE)
 
Among 20 OP cases, the length of cycle is 28 days cycle in 0(0%) cases, 
45 days cycle in 4(40%) cases, 45
cycle in 10(50%) cases. 
Among 20 IP cases, 28 days cycle in 0(0%)case, 28
cases, 45-60 days cycle in 7(35%) cases, above 60 days cycle in 10(50%) cas
0
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0
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BEFORE 
 OP PATIENTS IP PATIENTS
Nil 0 0 0 0
Mild 4 20% 3 15%
Moderate 6 30% 7 35%
Severe 10 50% 10 50%
20 100% 20 100%
-60 days cycle in 6(30%) cases, above 60 days 
-45 days cycle in 3(15%) 
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21.(b) DURATION OF BLEEDING SCORE 
Table: 21 (b): Distribution  of bleeding score 
GRADE BEFORE 
LENGTH OF THE CYCLE OP PATIENTS IP PATIENTS 
0 3 – 5 days Nil 10 50% 11 55% 
1 1 – 2/6-7 days Mild 4 20% 6 30% 
2 1/8-9days Moderate 2 10% 2 10% 
3 Spotting />9 days Severe 4 20% 1 5% 
Total 20 100% 20 100% 
 
FIGURE – 21(b) (DURATION OF BLEEDING SCORE) 
 
Among 20 OP cases, the duration of bleeding is 3-5 days in 10 (50%) cases,1-
2/6-7 days in 4(20%) cases,1 / 8-9 days in 2 (10%) cases, spotting / >9 days in 
4(20%) cases. 
Among 20 IP cases, 3-5 days in 11(55%) cases, 1-2 / 6-7 days in 6 (30%) 
cases,1 / 8-9 days in 2(10%) cases, spotting / >9 days in 1(5%) case. 
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22.CLINICAL SYMPTOMS BEFORE TREATMENT 
Table: 22: Distribution of clinical symptoms before treatment 
CLINICAL 
FEATURES 
OP PATIENTS IP PATIENTS 
NO. OF 
CASES 
PERCENTAGE 
NO. OF 
CASES 
PERCENTAGE 
Irregular 
menstruation 
18 90% 19 95% 
Amenorrhoea 11 55% 10 50% 
Oligomenorrhoea 5 25% 7 35% 
Hypermenorrhoea 5 25% 3 15% 
Dysmenorrhoea 10 50% 8 40% 
Weight gain 14 70% 13 65% 
Infertility 9 45% 4 20% 
Acanthosis 
nigricans 
8 40% 10 50% 
Hirsutism 4 20% 5 25% 
Acne 9 45% 3 15% 
Androgenic hair 
loss 
- - - - 
 
 
 
 
 
 
 
 
 
 FIGURE – 22 CLINICAL SYMPTOMS BEFORE TREATMENT
 
 
Among 20 OP cases, irregular menstruation was seen in 18 (90%) cases, 
amenorrhoea in 11(55%) cases, 
in 5(25%) cases, dysmenorrhea in 10(50%) cases, weight gain in 14(70%) cases, 
infertility in 9(45%) cases, acanthosis nigricans in 8(40%) cases, hirsutism in 4
cases, acne in 9 (45%)cases.
Among 20 IP cases, irregular menstruation was seen in 19 (95%) cases, 
amennorhoea in 10(50%) cases, oligomenorrhoea in 7(35%) cases, hypermenorrhoea 
in 3(15%) cases, dysmenorrhea in 8(40%) cases, weight gain in 13(65%) cases, 
infertility in 4(20%) cases, acanthosis ni
acne in 3(15%) cases. 
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oligomenorrhoea in 5(25%) cases, hypermenorrhoea 
 
gricans in 10(50%) cases, hirsutism in 5 (25
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 (20%) 
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 23.(a) INTERMENSTRUAL PERIOD ASSESSMENT SCORE 
Table: 23. Distribution of Intermenstrual period assessment score
 
GRADE 
 
 
LENGTH OF THE 
CYCLE 
BEFORE
cases
0 28 days Nil 0
1 
28-45 
days 
Mild 4
2 
45-60 
days 
Moderate 6
3 
Above 
60 days 
Severe 10
Total 20
 
 
FIGURE – 23(a) INTERMENSTRUAL PERIOD  ASSESSMENT SCORE
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OP PATIENTS IP PATIENTS
 AFTER BEFORE 
 % 1C % 2C % cases % 1C %
 0 0 0 0 0 0 0 0 0
 20% 8 40% 13 75% 3 15% 15 75%
 30% 12 60% 7 35% 7 35% 5 25%
 50% 0 0 0 0 10 50% 0 0
 100% 20 100% 20 100% 20 100% 20 100%
AFTER 
OP 2C
BEFORE 
IP
AFTER 
IP 1C
AFTER 
IP 2C
28 days
28-45 days
45-60days
Above 60days
 
AFTER 
 2C % 
 0 0 
 17 85% 
 3 15% 
 0 0 
 20 100% 
 
 
100 
 
1 C - First Menstrual Cycle; 2 C - Second Menstrual Cycle 
Among 20 OP cases, , 4(200%) cases were mild, 6(35%) cases were moderate 
and 10(50%) cases were severe, In first cycle 0(0%) cases - normal, 8(40%) cases - 
mild, 12(60%) case - moderate, 0(0%) cases - severe. In second cycle 0(0%) case - 
normal, 13(65%) cases - mild, 7(35%) cases – moderate, 0(0%) cases were severe. 
 
Among 20 IP cases, 0(0%) was normal, 3(15%) were mild, 7(35%) were 
moderate and 10(50%) cases were severe. In first cycle 0(0%) cases - normal, 
15(75%) cases - mild, 5(25%) cases - moderate, 0(0%) cases - severe. In second 
cycle 0(0%) cases - normal, 17(85%) cases - mild, 3(15%) case – moderate, 0(0%) 
cases - severe. 
 
23. (b) DURATION OF BLEEDING 
Table: 23 (b) Duration of  bleeding 
GRADE OP PATIENTS IP PATIENTS 
LENGTH OF THE 
CYCLE 
BEFORE AFTER BEFORE AFTER 
cases % 1C % 2C % cases % 1C % 2C % 
0 
3-5 
days 
Nil 6 30% 13 65% 16 80% 11 55% 16 80% 18 90% 
1 
1-2/6- 
7days 
Mild 3 15% 4 20% 3 15% 6 30% 3 15% 2 10% 
2 
1/8-9 
days 
Moderate 9 45% 3 15% 1 5% 2 10% 1 5% 0 0 
 
3 
Spotting 
>9 days 
 
Severe 
 
2 
 
10% 
 
0 
 
0 
 
0 
 
0 
 
1 
 
5% 
 
0 
 
0 
 
0 
 
0 
Total 20 100% 20 100% 20 100% 20 100% 20 100% 20 10% 
 
 
 
 
 
 FIGURE – 23(b) DURATION OF BLEEDING
 
 
1 C - First Menstrual Cycle; 2 C 
Among 20 OP cases, 6(30%) cases the DOB was normal, 3(15%) cases 
9(45%) cases - moderate and 2(10%) cases 
normal, 4(20%) case - mild, 3(15%) case 
- normal, 3(15%) cases – 
Among 20 IP cases, 11(55%) cases the DOB was normal, 6(30%) cases 
mild, 2(10%) cases - moderate, 1(5%) case 
normal, 3(15%) case- mild, 1(5%) case 
normal, 2(10%) case – mild, 0(0%) case
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- Second Menstrual Cycle 
- severe. In first cycle 13(65%) cases 
- moderate, In second cycle 16(80%) cases 
mild, 1(5%)cases-moderate. 
- severe. In first cycle 16(80%) cases 
- moderate. In second cycle 18(90%
-moderate. 
03-05 days
1-2/6-7days
1/8-9days
Spotting >9 days
 
- mild, 
- 
- 
- 
) cases - 
 24.CLINICAL SYMPTOMS BEFORE AND AFTERTREATMENT 
Table:24: Distribution of clinical symptoms before and after treatment
 
CLINICAL 
FEATURES 
OP PATIENTS
Cases 
observed
Irregular menstruation 18 
Amenorrhoea 11 
Oligomenorrhoea 5 
Hypermenorrhoea 5 
Dysmenorrhoea 10 
Weight gain 14 
Infertility 9 
Acanthosis nigricans 8 
Hirsutism         4
Acne 9 
Androgenic hair loss - 
 
FIGURE – 24 CLINICAL SYMPTOMS BEFORE AND AFTER  
TREATMENT 
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 IP PATIENTS 
 
% Cases 
improved 
% Cases 
observed 
% Cases 
improved
90% 13 73% 19 95% 14 
55% 7 64% 10 50% 7 
25% 5 100% 7 35% 7 
25% 4 80% 3 15% 0 
50% 7 70% 8 40% 0 
70% - - 13 65% - 
30% - - 4 20% - 
40% - - 10 50% - 
 60% - - 5 40% - 
20% - - 3 10% - 
- - - - - - 
0% 50% 100%
Cases improved in IP
Cases observed in IP
Cases improved in IP
Cases observed in OP
 
 
 
% 
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33% 
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Out of 20 OP cases, In 18(85%) cases the menstrual cycle was irregular before 
treatment and improved in 13(74%) cases after treatment, Amenorrhoea 11(55%) 
were seen in before treatment and improved in 7(64%) cases after treatment, 
Oligomenorrhoea were seen in 5(25%) cases before treatment and improved in 
5(100%) cases after treatment. Hypermenorrhoea were seen in 5(25%) cases before 
treatment and improved in 4(80%) cases after treatment. Dysmenorrhoea were seen in 
10(50%) cases before treatment and improved in 7(70%) cases aftertreatment. 
 
Out of 20 IP cases, irregular menstruation was seen in 19(95%) cases before 
treatment and improved in 14 (74%) cases after treatment. Amenorrhoea 10(50%) 
were seen in before treatment and improved in 7(70%) cases after treatment, 
Oligomenorrhoea were seen in 7(35%) cases before treatment and improved in 
7(100%) cases after treatment. Hypermenorrhoea were seen in 3(15%) cases before 
treatment and improved in 1(33%) cases after treatment. Dysmehorrhoea were seen in 
8(40%) cases before treatment and improved in 2(25%) cases after treatment. 
 25.CHANGES IN USG ABDOMEN AFTERTREATMENT
Table: 25: Distribution of usg abdomen after treatment
IMPROVEMENT 
USG Abdomen 
Good 
Complete clearance 
Moderate 
Changes in the size 
Poor 
 
 
Figure:25 CHANGES IN USG ABDOMEN AFTER TREATMENT
 
 
In 20 OP cases, complete clearance of cyst was seen in 2(10%) cases,changes 
in size of the cyst was seen in 15(75%) cases and no changes observed in 3(15%) 
cases. 
In 20 IP cases, complete clearance of cyst was seen in 1(5%) cases, changes in 
size of the cyst was seen in 13(65%) cases and no changes observed in 6(30%) cases
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changes 
OP IP
NO. OF 
CASES 
% 
NO. OF 
CASES 
of the cyst 
2 10% 1 
of the cyst 
15 75% 13 
No changes 3 15% 6 
Total 20 100% 20 
 
OP
IP
Moderate
Poor
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5%
65%
30%
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Table 26. BIOSTATISTICS BEFORE AND AFTER KARUNJCHIRAKAM  
CHOORANAM INTERVENTION 
VARIABLE 
BEFORE 
TREATMENT 
Mean ± SD 
AFTER 
TREATMENT 
Mean ± SD 
P 
VALUE 
RESUL
T 
BMI 26.0258 ± 3.7596 25.5190 ± 3.6638 <0.0001 HS 
Waist Hip Ratio 0.8665 ± 0.0695 0.8232 ± 0.0731 <0.0001 HS 
Size of the cyst 
BFT 
5.925 ± 2.19 4.5875± 2.50 <0.0001 HS 
Duration of 
bleeding 
6.3250± 2.36 
1C 2C 
<0.0001 HS 4.95 ± 
1.72 
4.50 ± 
1.30 
*HS – HIGHLY SIGNIFICANT 
*SD – STANDARD DEVIATION 
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1. BMI SCORE BEFORE AND AFTERTREATMENT 
 
 
S.No 
 
OP No 
OP 
 
IP No 
IP 
Before After Before After 
1 31084 24 23.56 1938 27.87 27.87 
2 33039 24.97 24.56 1939 23.7 22.64 
3 32999 23.74 22.83 2786 21.48 20.7 
4 33405 27.95 27.9 2928 21.33 20.67 
5 44385 22.68 22.44 443 24.34 23.53 
6 44938 39 38.53 517 27.39 26.48 
7 49374 27.34 28.13 518 24.97 23.73 
8 50040 28.51 28.51 538 23.56 22.22 
9 52701 22.23 21.51 788 24.97 24.56 
10 61282 34.17 33.11 789 30.67 30 
11 61349 29.33 29.56 948 25.3 24.88 
12 11405 26.35 25.41 949 26.4 25.44 
13 12241 30.26 29.36 1326 27.43 26.67 
14 14539 24.22 23.44 1404 22.22 22.22 
15 15365 19.63 20.9 1405 26.17 25.59 
16 15348 27.78 27.39 1408 23.14 22.68 
17 16457 25.4 24.86 1393 28.52 27.73 
18 16336 25.16 24.61 1495 26.35 25.59 
19 16338 21.45 21.64 1496 28.89 28.6 
20 17460 21.36 21.79 1497 30.8 28.92 
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2.WAIST HIP RATIO BEFORE AND AFTERTREATMENT 
 
S.No 
 
OP No 
OP 
 
IP No 
IP 
Before After Before After 
1 31084 0.90 0.87 1938 1.03 0.91 
2 33039 0.75 0.69 1939 0.92 0.88 
3 32999 0.93 0.97 2786 0.75 0.71 
4 33405 0.92 0.80 2928 0.79 0.79 
5 44385 0.82 0.80 443 1.0 0.98 
6 44942 0.91 0.74 517 0.75 0.68 
7 49374 0.91 0.91 518 0.95 0.90 
8 50040 0.78 0.80 538 0.90 0.83 
9 52701 0.83 0.83 788 0.91 0.86 
10 61282 0.85 0.85 789 0.87 0.82 
11 61349 0.76 0.83 948 0.90 80 
12 11405 0.80 0.75 949 0.92 0.90 
13 12241 0.88 0.82 1326 0.86 0.87 
14 14539 0.82 0.78 1404 0.80 0.72 
15 15365 0.83 0.82 1405 1.0 0.89 
16 15348 0.90 0.87 1408 0.80 0.82 
17 16457 0.88 0.85 1393 0.89 0.79 
18 16336 0.83 0.80 1495 0.87 0.84 
19 16338 0.90 0.90 1496 0.86 0.80 
20 17460 0.79 0.65 1497 0.90 0.79 
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3.CASE SUMMARY OF OUTPATIENTS 
S.No OP No Name Age Sex Date of 
admission 
Date of 
discharge 
Duration of 
illness 
Treatment with 
dose 
Total no. of 
days treated 
1 31084 Aneesh fathima 24 F 03/04/18 01/06/18 3 years 
KARUNJCHIRAKAM 
CHOORANAM 
2gm BD 
60 days 
2 33039 Balarasheedha 26 F 10/04/18 09/06/18 2 years 60 days 
3 32999 Dona 34 F 10/04/18 09/06/18 5 years 60 days 
4 33405 Karthika 27 F 13/04/18 12/06/18 5 years 60 days 
5 44385 Ramalakshmi 28 F 22/05/18 20/07/18 5 years 60 days 
6 44942 Mookkammal 19 F 23/05/18 21/07/18 1year 60 days 
7 49374 Feliciya 19 F 09/06/18 07/08/18 2 years 60 days 
8 50040 Samyuktha 18 F 12/06/18 10/08/18 1year 60 days 
9 52701 Janaki 30 F 21/06/18 19/08/18 3 years 60 days 
10 61282 Nilofer 24 F 23/07/18 10/09/18 2 years 60 days 
11 61349 Alagurani 25 F 23/07/18 10/09/18 5 years 60 days 
12 11405 Subhasree 18 F 10/01/19 10/03/19 1 year 60 days 
13 12241 Saranya 26 F 03/02/19 03/04/19 4 years 60 days 
14 14539 Subhashini 22 F 08/02/19 09/04/19 2 years 60 days 
15 15365 Basariya 27 F 11/02/19 11/04/19 4 years 60 days 
16 15348 Suba 19 F 11/02/19 11/04/19 1 year 60 days 
17 16457 Pathmavathi 27 F 14/02/19 14/04/19 3 years 60 days 
18 17460 Subbulakshmi 29 F 14/02/19 14/04/19 3 years 60 days 
19 16336 Nishanthini 28 F 15/02/19 15/04/19 4 years 60 days 
20 16338 Subbulakshmi 28 F 16/02/19 16/04/19 2 years 60 ays 
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4. CASE SUMMARY OF INPATIENTS 
S.No IP No Name Age Sex 
Date of 
admission 
Date of 
discharge 
Duration 
of illness 
Treatment with 
dose 
No. of days treated Total no. of 
days treated IP Follow 
1 1938 Ananthammal 25 F 30/07/18 13/08/18 3 years 
KARUNJCHIRAKAM 
CHOORANAM 
-2gm BD 
15 days 45 days 60 days 
2 1939 Knniyammal 43 F 30/07/18 13/08/18 4 years 15 days 45 days 60 days 
3 2786 Ponrani 39 F 15/11/18 12/01/19 1 year 59 days 1 day 60 days 
4 2928 Usha 36 F 29/11/18 19/01/19 1 ½ years 52 days 8 days 60 days 
5 443 Dhivya 28 F 21/02/19 10/04/19 2 years 49 days 11 days 60 days 
6 517 Ramalakshmi 39 F 28/02/19 12/04/19 1 year 44 days 16 days 60 days 
7 518 Rajapriya 36 F 28/02/19 07/03/19 4 years 8 days 52 days 60 days 
8 538 Abirami 37 F 12/03/19 12/04/19 2years 32 days 28 days 60 days 
9 788 Nallammal 41 F 27/03/19 10/05/19 2 years 45 days 15 days 60 days 
10 789 Mahalakshmi 35 F 27/03/19 10/05/19 1 year 45 days 15 days 60 days 
11 948 Subbulakshmi 39 F 15/04/19 05/05/19 2 years 21 days 39 days 60 days 
12 949 Muthulakshmi 41 F 15/04/19 05/05/19 1 year 21 days 39 days 60 days 
13 1326 Valli 21 F 02/05/19 29/05/19 1 year 28days 32days 60 days 
14 1404 Janaki 39 F 03/05/19 26/06/19 3½ years 54 days 6 days 60 days 
15 1405 Sujatha 40 F 03/05/19 14/06/19 3 years 43 days 17 days 60 days 
16 1408 Ganthimathi 40 F 03/05/19 22/05/19 2 years 20days 40 days 60 days 
17 1393 Gracy 24 F 5/05/19 14/06/19 3 years 45 days 15 days 60 days 
18 1495 Sudha 18 F 9/05/19 26/06/19 1 year 49days 11 days 60 days 
19 1496 Muthaparanam 39 F 09/05/19 25/06/19 3½ years 48 days 12 days 60 days 
20 1497 Subbulakshmi 40 F 09/05/19 26/06/19 3 years 49 days 11 days 60 ays 
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5.LABORATORY INVESTIGATION OF OUTPATIENTS 
S.N 
o 
OP 
No. 
HEMATOLOGICAL INVESTIGATIONS BIOCHEMICAL ANALYSIS URINE ANALYSIS 
BT 
HB 
% 
AT 
HB 
% 
BT AT BT AT BT AT 
TC 
DC 
TC 
DC ESR mm/hrs 
Sug Ur ea Ch ole Sug Ure a Chole Alb Sug Dep Alb Sug Dep 
P L E P L E ½ 1 ½ 1 
1 31084 8400 61 35 2 8.4 9005 60 32 6 10.4 11 27 19 31 129 25 186 107 23 127 Nil Nil NAD Nil Nil NAD 
2 33039 7100 62 37 4 8.2 8107 67 34 5 9.7 12 28 3 17 108 17 198 97 24 148 Nil Nil NAD Nil Nil NAD 
3 32999 8300 60 34 6 9.1 8907 65 35 4 9.6 13 29 5 14 93 15 175 106 27 145 Nil Nil NAD Nil Nil NAD 
4 33405 7700 66 37 3 8.3 8109 60 38 3 9.7 12 20 6 15 103 13 142 109 18 129 Nil Nil 1-2pus 
cells Nil Nil NAD 
5 44385 7600 66 26 4 14 7108 66 37 4 11.3 5 19 7 17 114 13 183 108 26 157 Nil Nil NAD Nil Nil NAD 
6 44942 8600 65 29 9 9.6 8802 62 30 1 10.5 10 26 8 17 85 16 153 98 25 185 Nil Nil NAD Nil Nil NAD 
7 49374 9200 69 27 7 11.1 8701 53 40 5 10 24 47 15 37 97 14 173 96 29 148 Nil Nil NAD Nil Nil NAD 
8 50040 9500 43 50 5 10.2 8804 64 36 6 11.5 16 25 23 5 86 25 154 95 16 130 Nil Nil NAD Nil Nil NAD 
9 52701 8800 57 39 6 8.7 9005 67 38 7 10.4 25 27 5 18 95 27 173 93 29 149 Nil Nil NAD Nil Nil NAD 
10 61282 8200 58 3 4 8.2 8709 69 36 1 9.6 24 46 16 29 114 15 185 103 26 179 Nil Nil NAD Nil Nil NAD 
11 61349 8603 66 30 7 9.0 8703 63 39 5 9.8 37 61 14 34 122 19 171 116 23 149 Nil Nil NAD Nil Nil NAD 
12 11405 9804 55 30 3 10 8704 65 39 6 10.6 9 25 9 15 103 10 152 104 28 147 Nil Nil NAD Nil Nil NAD 
13 12241 8205 69 30 8 12.7 8109 67 38 8 16 39 66 17 36 74 29 124 88 26 150 Nil Nil NAD Nil Nil NAD 
14 14539 9004 65 30 5 10.4 8200 69 37 9 10.7 20 47 18 27 116 28 165 107 27 140 Nil Nil NAD Nil Nil NAD 
15 15365 7804 67 20 7 12.4 8105 60 39 7 10.9 10 40 17 35 68 27 146 84 28 120 Nil Nil NAD Nil Nil NAD 
16 15348 8805 68 30 6 8.7 8205 67 30 5 9.0 8 10 9 16 99 26 177 87 26 157 Nil Nil NAD Nil Nil NAD 
17 16457 7906 62 30 9 10.7 8404 60 26 6 11.9 19 28 7 15 89 16 218 85 26 189 Nil Nil 1-2pus 
cells Nil Nil NAD 
18 17460 7607 63 30 5 9.7 7008 75 26 2 11.7 10 39 15 26 90 25 155 73 27 190 Nil Nil NAD Nil Nil NAD 
19 16336 9006 57 40 7 8 8209 66 30 8 8.6 9 10 6 5 70 14 129 84 28 116 Nil Nil NAD Nil Nil NAD 
20 16338 8703 68 29 9 15 8809 50 47 9 13.4 8 19 3 13 92 13 144 105 29 169 Nil Nil NAD Nil Nil NAD 
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6.LABORATORY INVESTIGATION OF INPATIENTS 
S.No. IP 
No. 
HEMATOLOGICAL INVESTIGATIONS BIOCHEMICAL ANALYSIS URINE ANALYSIS 
BT HB 
% 
AT HB 
% 
BT AT BT AT BT AT 
TC DC  
TC 
DC ESR mm/hrs  
Sug 
Urea Chole Sug Ure a Chole Alb Sug Dep Alb Sug Dep 
P L E P L E ½ 1 ½ 1 
1 1938 8004 60 35 5 11.8 8206 61 36 2 13 2 10 9 12 83 14 143 95 12 158 Nil Nil NAD Nil Nil NAD 
2 1939 8405 62 39 7 8.8 7806 62 38 4 9.4 4 18 7 4 124 16 214 96 13 177 Nil Nil NAD Nil Nil NAD 
3 2786 6808 62 34 9 10 8906 64 37 7 11.4 15 35 6 25 96 25 215 96 14 188 Nil Nil 1-2 pus 
cells 
Nil Nil NAD 
4 2928 7507 54 45 7 11.1 7807 65 38 8 11.5 44 4 5 16 87 16 166 107 15 167 Nil Nil NAD Nil Nil NAD 
5 443 9508 63 39 8 10.6 8508 56 39 4 10 17 33 17 27 148 15 157 127 14 168 Nil Nil NAD Nil Nil NAD 
6 517 8406 65 39 9 8 8609 57 30 7 9.5 15 32 13 25 79 16 158 88 16 169 Nil Nil NAD Nil Nil NAD 
7 518 7808 65 38 4 12.9 8007 57 49 2 10.9 18 22 18 26 90 18 169 107 17 188 Nil Nil NAD Nil Nil NAD 
8 538 8105 76 29 5 9.9 8808 78 28 4 10.7 14 27 17 26 119 29 239 118 28 208 Nil Nil NAD Nil Nil NAD 
9 788 7209 69 28 7 8.7 7109 69 38 9 9.6 7 10 6 14 87 18 208 99 17 188 Nil Nil 1-4 pus 
cells 
Nil Nil NAD 
10 789 6901 67 38 8 10 7207 60 37 8 17 9 9 7 17 86 27 199 88 28 199 Nil Nil NAD Nil Nil NAD 
11 948 7502 70 22 3 9.4 8604 54 36 6 10.5 23 56 13 28 84 25 225 112 22 152 Nil Nil NAD Nil Nil NAD 
12 949 7903 69 33 2 12.8 8306 55 44 4 14 32 70 14 38 75 25 215 94 24 182 Nil Nil 1-2 pus 
cells 
Nil Nil NAD 
13 1326 8004 58 34 8 11.5 9007 56 35 5 11 14 37 19 27 126 36 167 102 25 143 Nil Nil NAD Nil Nil NAD 
14 1404 9004 68 25 7 7.9 8809 67 25 6 3 15 28 10 20 67 15 139 73 14 133 Nil Nil NAD Nil Nil NAD 
15 1405 8305 66 36 6 10.6 8208 68 36 8 10.5 16 20 14 26 128 25 200 132 27 194 Nil Nil NAD Nil Nil NAD 
16 1408 8006 65 27 5 9.4 7607 59 37 7 10 17 32 10 25 107 18 183 92 28 165 Nil Nil NAD Nil Nil NAD 
17 1393 7107 66 37 3 12.7 7505 60 28 8 16 3 6 4 14 138 15 194 123 16 194 Nil Nil NAD Nil Nil NAD 
18 1495 8600 65 38 5 9.8 7604 64 37 8 13 10 20 6 15 117 16 153 102 28 135 Nil Nil 1-4 pus 
cells 
Nil Nil NAD 
19 1496 8207 54 49 4 10.9 8700 73 22 9 10.2 17 39 5 14 134 25 166 100 29 144 Nil Nil NAD Nil Nil NAD 
20 1497 8508 63 30 5 11.4 8803 65 26 3 10.8 22 44 42 25 125 34 187 102 20 143 Nil Nil NAD Nil Nil NAD 
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CHAPTER - VI  
DISCUSSION 
 Raktha Soorai Vaayu is one of the disease ,which it was described in the text 
Yugimuni Vaithiya Kaviyam. It is characterised by absence or irregular of 
menstruation, heavy menstrual bleeding, menstrual pain and miscarriage. The 
symptoms are correlated  in modern medicine is Poly Cystic Ovarian 
Syndrome. The clinical study was conducted in 40 cases after screening the 
patients. 20 cases were studied  in Outpatient Department and 20 cases were 
admitted in Inpatient Department of Govt. Siddha Medical 
College,Palayamkottai. 
 The trial drug  Karunjchirakam chooranam is given twice daily after food for 
60days. 
 The clinical assessment was recorded for every 15days. 
 The observations are summarized below. 
 
1. Distribution of cases by age: 
The 20 OP cases the prevalence was found to be higher in 13 cases (65%) in 
the age group of 26-35 years. 20 IP cases the prevalence was found to be higher in 14 
cases (70%)  in the age group of 36-45years. 
 
2. Distribution of cases by marital status: 
The  20 OP cases the prevalence of disease was found to be higher in 
unmarried females i.e. 11cases (55%).IP cases the prevalence of disease was found to 
be higher in married females i.e. 17 cases (85%). 
 
3. Distribution of cases by parity: 
Among 11 OP cases, 9 (82%) cases were found to be nulliparous and 2(18%) 
cases were found to be multiparous. 17 IP cases, 4(23.52%) cases were found to be 
nulliparous,  10(58.82%) cases were found to be uniparous and 3(17.64%) cases were 
found to be multiparous. 
 
4. Distribution of cases by Religion: 
Among 20 OP cases, 14 (70%) cases were Hindus, 2(10%) cases were 
Christians and 4(20%) case wasMuslim. 20 IP cases, 19(95%) cases were Hindus and 
1(5%) cases were Christians and 0(0%) case was Muslim. 
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5. Distribution of cases by Paruva kaalam: 
The 20 OP cases, for 8(40%) cases the treatment period was Munpanikaalam 
and 5(25%) cases it was Pinpanikaalam.and 4(20% )cases it was ilavenilkaalam, and 
3(15%)cases it was mudhuvenilkaalam. 20 IP cases, for 2(10%) cases the treatment 
period was koothirkaalam,8(40%), cases it was Pinpanikaalam and 8(40%) cases it 
was Ilavenilkaalam  and 2(10%) cases it was mudhuvenilkaalam  
 
6. Distribution of cases by Thinai: 
The 20 OP cases, 4(20%) were from the land Kurinji, 14(70%) were from the 
land Marutham and 2(10%) was from the landNeithal.The 20 IP cases, 3(15%) were 
from the land Kurinji, 16(80%) were from the land Marutham and 1(5%) were from 
the land Mullai. 
 
7. Distribution of cases by Diet: 
The 20 OP cases, majority of the cases i.e. 18(90%) were Non-
vegetarians.The 20 IP cases, majority of the cases i.e. 19(95%) were Non - 
vegetarians. 
 
8. Case distribution: 
The 20 OP cases 9(45%) cases were diagnosed with PCOS only, 9(45%) cases 
were PCOS with primary infertility and 2(10%) cases were PCOS seen in fertile 
women. 
The 20 IP cases, 3(15%) cases were diagnosed with PCOS only, 4(20%) cases 
were PCOS with primary infertility and 13(65%) cases were fertile women with 
PCOS. 
 
9. Distribution of cases by Body built: 
The 20 OP cases, majority of the cases i.e. 8 (40%) cases were overweight and 
6 cases (35%) were normal weight. 
The  20 IP cases, majority of cases i.e.10 (50%) cases were overweight. 
 
10. Distribution of cases byoccupation: 
The 20 OP cases, the incidence was more in students i.e. 10 cases (50%). The 
20 IP cases, the incidence was more in non-employee i.e. 14 cases (70%). 
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11. Distribution of cases by positive familyhistory: 
The 20 OP cases, only 2(10%) cases had positive familial history. The 20 IP 
cases, only 1(5%) case had positive familial history. 
 
12. Distribution of cases by chronicity of illness:  
 The 20 OP cases (irregularmenstruation) 
  In 0(0%) case had the duration of illness were less than 6 months,  
 4 (20%) cases were between 6 months – 1 year,  
5 (25%) cases were between 1- 2 years,  
11(55%) cases were between 2 – 5 years, 
The 20 OP cases, majority of the cases the chronicity of the illness was 
between 2-5 years 
The  20 IP cases, 
6(30%) cases were between 6 months – 1 year, 
6 (30%) cases were between 1 – 2 years, 
8 (40%) cases were between 2 – 5 years, 
0 (0%) case was between 5 – 10 years and 
Among 20 IP cases, majority of the cases the chronicity of the illness was 
between 2-5 years. 
The chronicity of illness i.e. infertility before recruitment for the study,  
In 9 OP study,  
In 4 (14.44%) case the chronicity of illness was between 1-2 yrs. In 5 
(55.55%) cases the chronicity of illness was between 3-5 years. In 0(0%) case the 
chronicity of illness was between 6-10 years. In OP study majority of cases were 
between 3-5 years.  
In 4  IP study, 
In 3 (75%) case the chronicity of illness was between 1-2 years. In 1 (25%) 
case the chronicity of illness was between 3-5 years. In IP study majority of cases 
were between 1-2 years. 
 
13. Treatment history: 
In 20 OP cases, among 9  infertility cases, 4(44.44%) cases underwent 
treatment for ovulation induction, 5 case (55.55%) had not taken anytreatment. 
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In 20 IP cases, among 4 infertility cases, 2(50%) cases underwent treatment 
for ovulation induction, 2 case (50%) had not taken anytreatment. 
In OP study, among 9  PCOS cases, 5 cases (56%) had undergone treatment 
for menstrual induction, 4 cases (44%) had not undergone any treatment. 
In IP study, among 4  PCOS cases, 2(50%) had undergone treatment for 
menstrual induction and 2 cases (50%) had not undergone any treatment before. 
 
14. Thegi: 
In 20 OP cases,the majority of the cases i.e. 9(45%) were Thonthathegi . In 20 
IP cases, the majority of the cases i.e. 8(40%) were Thonthathegi. 
15.Mukkutram: 
15. a.Derangement in Vathakutram:  
The  20 OP cases, 
Abanan was affected in 20(100%) cases. Samanan was affected in 20(100%) 
cases. Viyanan was affected in 20(100%) cases. Devadhathan was affected in 
16(80%) cases. 
The  20 IP cases, 
Abanan was affected in 20(100%) cases. Samanan was affected in 20(100%) 
cases. Viyanan was affected in 20(100%) cases. Devadhathan was affected in 
15(75%) cases. 
 
15 .b. Derangement in Pithakutram:  
IN  20 OP cases, 
Ranjagam was affected in 5(25%) cases. 
IN  20 IP cases, 
Ranjagam was affected in 3(15%) cases. 
15. c. Derangement in Kapha kutram: 
In 20 OP cases, santhigam was affected in 7(35%) cases. In 20 IP cases, 
santhigam was affected in 6(30%) cases. 
 
16. Distribution of cases by Gnanenthriyam:  
The 20 OPcases, 
Mei was affected in 8(40%) cases. Kan was affected in 5(25%) cases. 
Vaai, mooku and sevi were found to be normal in all cases. 
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The  20 IP cases, 
Mei was affected in 10(50%) cases. Kan was affected in 3(15%) cases. 
Vaai, mooku and sevi were found to be normal in all cases. 
17. Distribution of cases byKanmenthriyam: 
Among 20 OP cases, 
Karuvaai was affected in 20(100%) cases. 
Kai, kaal , vaai  and  Eruvaai  were found to be normal in all cases. 
Among 20 IP cases, 
Karuvaai was affected in 20(100%) cases.  
Kai, kaal ,vaai , and  Eruvaai  were normal in all cases. 
18. Kosangal: 
Among 20 OP cases, 
In 20(100%) cases, Ananthamayakosam was affected. Annamayakosam, 
Pranamayakosam, Vignanamayakosam and Manomayakosam were normal in all 
cases. 
Among 20 IP cases, 
In 20(100%) cases Ananthamayakosam was affected. Annamayakosam, 
Pranamayakosam, Vignanamayakosam and Manomayakosam were normal in all 
cases. 
 
19. Distribution of cases by UdalThathukkal:  
Among 20 OPcases, 
Senneer was affected in 5(25%) cases. Kozhuppu was affected in 11(55%) 
cases. Suronitham was affected in 20(100%) cases. 
Saaram, Oon, Enbu and Moolai were not affected in all cases. 
Among 20 IP cases, 
Senneer was affected in 3(15%) cases. Kozhuppu was affected in 12(60%) 
cases. Suronitham was affected in 20(100%) cases. 
Saaram, Oon, Enbu and Moolai were not affected in all the cases. 
20. Distribution of cases by Envagaithervugal:  
The 20 OPcases, 
All are  normal. 
The  20 IP cases, 
All  are normal. 
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20. a.Distribution of cases by Naadi type:  
The 20 OP cases, 
Vathapithanaadi and kaphavathanaadi were predominant in 7(35%) cases 
each. 
Pithavatha naadi in 5(25%) cases. Vathanaadi was found in 1(5%) case. 
The 20 IP cases, 
Kaphavathanaadi was predominant in 9(45%) cases. Vathapithanaadi was 
found in 6(30%) cases. 
Pithavathanaadi was found in 4(20%) case. Vathanaadi was found in 1(5%) 
case. 
20.b. Distribution of cases by Neikuri:  
In 20 OPcases, 
4(20%) cases had vathaneer pattern. 3(15%) cases had pithaneer pattern. 
13(65%) cases had kapha neer pattern. 
In 20 IP cases, 
5(25%) cases had vathaneer pattern. 
3(15%) cases had pithaneer pattern. 12(60%) cases had kapha neer pattern. 
 
21. a. Intermenstrual period assessment before treatment:  
The  20 OPcases, 
0(0%) cases were in 28 days cycle,   4(20%) cases were in 28-45 days cycle, 
6(30%) cases were in 45-60 days cycle and 10(50%) cases were in above 60 
dayscycle. 
In this study, most of the cases 10(50%) fall under above 60 days cycle. 
The 20 IP cases, 
0 (0%) case were in 28 days cycle, 3(15%) cases were in 28-45 days cycle, 
7(35%) cases were in 45-60 days cycle and 10(50%) cases were in above 60 days 
cycle. 
In this study, most of the cases 10(50%) fall under above 60 days cycle. 
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21.b.Duration of bleeding phase scoring before treatment:  
In  20 OPcases, 
In 10(50%) cases the DOB was under grade 0 In 4(20%) cases the DOB was 
under grade 1 In 2(10%) cases the DOB was under grade 2 In 4(20%) cases the DOB 
was under grade 3 In OP study 10(50%)cases were under grade0. 
In  20 IP cases, 
In 11(55%) cases the DOB was under grade 0 In 6(30%) cases the DOB was 
under grade 1 In 2(10%) cases the DOB was under grade 2 In 1 (5%) cases the DOB 
was under grade 3 In IP study 11(55%) cases were in grade 0. 
 
22. Clinical symptoms before treatment 
Irregular menstruation was seen in 18(90%) cases, amenorrhoea in 11(55%) 
cases, oligomenorrhoea in 5(25%)cases, hypermenorrhoea in 5(25%) cases, 
dysmenorrhea in 10(50%) cases, weight gain in 14(70%)cases, infertility in 9(45%) 
cases, acanthosis nigricans in 8(40%) cases, hirsutism in 4(20%) case, acne in 9(45%) 
cases were observed in op cases. 
Irregular menstruation was seen in 19(95%) cases, amennorhoea in 10(50%) 
cases, oligomenorrhoea in 7(35%) cases, hypermenorrhoea in 3(15%) cases, 
dysmenorrhea in 8(40%) cases, weight gain in 13(65%) cases, infertility in 4(20%) 
cases, acanthosis nigricans in 10(50%) cases,hirsutism in 5(25) , acne in 3(15%) cases 
were affected in 20 cases of IP. 
 
OUTCOME MEASURES: 
PRIMARY OUTCOME OBSERVATIONS: 
23. a .INTERMENSTRUAL PERIOD ASSESSMENT SCORE 
The 20 OP cases, 
In 13(65%)cases there was days cycle. In7(35%) cases there was 45-60 days 
cycle. 
In 0(0%) cases there was above 60 days cycle. 
The  20 IP cases, 
In17(85%) cases there was 28-45days cycle .In 3(15%) case there was 45-60 
days cycle. 
In 0(0%) cases there was above 60 days cycle. 
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23.b. IMPROVEMENT IN DURATION OF BLEEDING SCORE 
IN OP cases, 
16(80%) cases had improved to grade 0 3(15%) cases had improved to grade 
1 1(5%) cases had improved to grade 2 
IN IP cases, 
18(90%) cases had improved to grade 0. 
2 (10%) cases had improved to grade 1   
24. IMPROVEMENT IN THE CLINICAL SYMPTOMS:  
The  20 OPcases, 
Regular menstrual cycle in 13 (73%) cases. 
After treatment there was a considerable reduction in the symptoms like 
oligomenorrhoea,dysmenorrhoea,hypermenorrhoea andamenorrhoea. 
The  20 IP cases, 
Regular menstrual cycle in 14(74%) cases. 
After treatment there was a considerable reduction in the symptoms like 
oligomenorrhoea, dysmenorrhoea, hypermenorrhoea andamenorrhoea. 
In both OP and IP there are no significant changes in the body weight. In both OP and 
IP Infertility cases had not conceived. 
 
25.ASSESSSMENT THROUGH USG PELVIS:  
Out of 20 OPcases, 
2(10%) cases showed complete clearance of the cyst. 15(75%) cases showed 
changes in the size of the cyst. 3(15%) cases showed no changes. 
Out of 20 IP cases. 
1(5%) cases showed complete clearance of the cyst. 13(65%) cases showed 
changes in the size of the cyst. 6(30%) cases showed no changes. 
 
26.BMI SCORE 
There is a mild improvement showed in after treatment,it was confirmed by 
the  BMI score. 
 
27.WAIST HIPRATIO: 
There is a reduced  the waist hip ratio. 
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CHAPTER - VII  
SUMMARY 
 The aim of the study is to document the efficacy of siddha medicine 
KARUNJCHIRAKAM CHOORANAM(Internal Medicine) in the treatment of 
RakthaSoorai Vaayu(Poly Cystic OvarianSyndrome) 
 The raw drug was authenticated by the botanist and the trial drug was 
prepared in the Gunapaadam Department of Government Siddha Medical 
College, Palayamkottai. 
 The medicine was subjected to preclinical studies in K.M.College of 
pharmacy, Madurai and acute toxicity studies in animal house of Govt. Siddha 
Medical College,Palayamkottai. 
 In preclinical study, biochemical and clinical parameters in a rat model of 
PCOS reveals that KARUNJCHIRAKAM CHOORANAM had induced 
recovery from Estradiol valerate (EV) induced PCO state in rats, probability 
of interaction of the GABA system, regulation of LH surge secretion, increase 
the size of dominant follicles and in the uterus it causes better endometrial 
tissue arrangements. 
 For the clinical study, 40 cases (20 OP and 20 IP) were recruited for the trial 
as per the inclusion and exclusion criteria and the informed consent were 
obtained from thepatients. 
 20 cases were treated in the OP Pothu Maruthuvam and 20 cases were 
admitted in IP ward of Govt. Siddha Medical College, Palayamkottai. Case 
sheet proforma was maintained both for OP and IPpatients. 
 The trial medicineKARUNJCHIRAKAM CHOORANAMwas given twice 
daily after food for sixtydays. 
 Laboratory investigations were carried out before and after the treatment and 
concerned data was recorded in theproforma. 
 USG pelvis was done before and after thetreatment. 
 Clinical assessments were done once in 15 days for all thepatients. 
 During the study period, there was no adverse eventreported. 
 In this study out of 40 cases, the improvement in the clinical symptoms were 
normal menstrual cycle i.e., 28-45 days cycle in 20(50%) cases and duration 
of menstrual bleeding(3-5days) in 34(85%)cases. 
 USG pelvis shows complete clearance of the cyst in 3(15%)cases 
121 
 
 Follicular study was done in 1 case and it shows no folliculardevelopment. 
 Mild improvement changes showed in the BMI and waist hip ratio before and 
after thestudy. 
 As per siddha text and recent research articles, the ingredient of the trail drug 
was found to have properties owing to the diseasemanifestations. 
 In acute toxicity study there was no mortality up to the dose level of 
300mg/kg body weight in experimentalmice. 
 This ensures the safety usage of the drug KARUNJCHIRAKAM 
CHOORANAMas per literature. 
 Biochemical and KARUNJCHIRAKAM CHOORANAMshowed the presence 
of Calciam, sulphate, chloride, , ferrous iron, Amino acid. 
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CHAPTER - VIII CONCLUSION 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing 
normal menstrual cycle i.e., 28 days cycle in 20(50%) cases and duration of 
bleeding (3-5days) in 34 (85%)cases. 
 USG pelvis shows complete clearance of cyst in 3 (15%) cases. 
 In Pharmacological studies resultd in a rat model of PCOS reveals that 
KARUNJCHIRAKAM CHOORANAM had induced recovery from Estradiol 
valerate (EV) induced PCO state in rats, probability of interaction of the 
GABA system, regulation of LH surge secretion, increase the size of 
dominant follicles and in the uterus it causes better endometrial tissue 
arrangements. 
 Preclinical studies biochemical, phytochemical and anti-microbial are resulted 
were carried out for the trial medicine of Karunjchirakam Chooranam 
 The acute toxicity studies conducted revealed that the trial drug was safe at 
higher dosage of 200 mg/kg body weight in experimental mice. 
 Biochemical analysis of KARUNJCHIRAKAM CHOORANAM showed 
the presence of sulphate, chloride, starch, ferrous iron, phosphate, unsaturated 
compound and aminoacid. 
 No adverse drug reactions were noticed during the course of treatment. 
 The trial drug is cost effective and easily preparable. 
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ANNEXURE 1 
PREPARATION OF KARUNJCHIRAKAM CHOORANAM 
Ingredient: 
            Karunjchirakam - Seeds only. 
 
                 
Purification  of  raw drug: 
Remove the dust particles and soaked it calcium carbonate water. Then allow 
it  to dry in shade light                                    
 
Methodology: 
The Karunjchirakam seeds were dried under sunlight and made into fine 
power. The powder is then filtered in pure white cloth. The prepared drug will be 
stored in clean and dry air – tight container. 
 
Dosage: 
2gm bd twice a day after food. 
Reference: 
Poem Ref: Gunapaadam mudhal paagam Mooligai Vaguppu – Pg .no: 463-
464 Chooranam preparation Ref:Gunapaadam Thathu Seeva vaguppu- paagam 2 & 3-
Pg.no: 60, 61.  
PROPERTIES OF TRIAL DRUG 
The trial drug is Karunjchirakam seeds. 
gVR<sQvgl<!(KARUNJCHIRAKAM) 
 
 
1. Botanical  Name  : Nigella sativa 
2. Family    : Renunculaceae 
3. Characters : 
Sju! ;!jgh<H!
ke<jl;!ouh<hl<!
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4. Chemical constituents: 
 Tymoquinone 
 Tymohytroquinone  
 Ditymoquinone  
 P-cymene 
 Carvacrol 
 4-terpineol 
 T-anethol 
 Sesquiterpene 
 Longifolene 
5. Pharmacological action: 
 Anti-diabetic 
 Anti-hypertensive 
 Liver tonic 
 Anti-bacterial 
 Diuretic 
 Emmenagogue 
 Anti-cancer 
 Immunomodulator 
 Anti-inflammatory 
 Anti-oxidant 
 Bronchodilator. 
 
 
 




















